I R B-3 1 9 1 3 versi o n 8  P a ge 1  of 4 6   2  Se pte m ber  2 0 2 0  A P h ase  2 cli nic al tri al of t he P A R P i n hi bit or t al az o p ari b i n B R C A 1 a n d B R C A 2 wil d -t y pe 
p atie nts wit h a d v a nce d tri ple -ne g ati ve bre ast c a ncer a n d h o m ol o g o us rec o m bi n ati o n 
deficie nc y or a d v a nce d H E R 2 -ne g ati ve bre ast c a ncer or ot her s oli d t u m o rs wit h a m ut ati o n 
i n h o m ol o g o us rec o m bi n ati o n p at h w a y ge nes 
C o or di n ati n g Ce nter  
Sta nf or d Ca ncer I nstit ute  
8 7 5 Bla ke Wil b ur Dri ve  
Sta nf or d, C A 9 4 3 0 5  
I n vesti g at ors 
Meli n d a  L  Telli,  M D  
Assista nt Pr ofess or of M e dici ne  
Di visi o n of O nc ol o g y  
Sta nf or d U ni versit y Sc h o ol of Me dic i ne 
8 7 5 Bla ke Wil b ur Dr,  Sta nf or d, C A  9 4 3 0 5  
Tele p h o ne : ;  Fa x:   
E mail:   J os h u a  Gr u ber,  M D,  P h D  
P ost -D oct oral Fell o w  
De part me nts of M e dici ne a n d Ge netics  
Sta nf or d U ni v ersit y Sc h o ol of Me dici ne  
3 1 6 5 P orter Dr,  Pal o Alt o, C A  9 4 3 0 4  
Tele p h o ne:  
E mail:  
Bi ost atistici a n  
Ale x Mc Milla n, P h D  
Se ni or Researc h Scie ntist  
Bi o me dical D ata Scie nce  
Sta nf or d  U ni versit y Sc h o ol of Me dici ne  
H R P Re d w o o d B uil di n g, R o o m T 1 6 0 A  
2 5 9 Ca m p us Dr,  Sta nf or d, C A  9 4 3 0 5  
P h o ne: ;  Fa x:  
E mail:  St u d y C o or di n at or  
W yatt  F orrest  Gr oss , B S  
8 0 0 Welc h R oa d, R o o m F C 3 C 4 5  
Sta nf or d, C A  9 4 3 0 4  
P h o ne: ;  Fa x:  
E mail:   
 
I R B-3 1 9 1 3  B R S 0 0 5 0  N C T 0 2 4 0 1 3 4 7  
Versi o n 8  / Versi o n Date:  0 2  Se pte m ber  2 0 2 0  
I R B-3 1 9 1 3 versi o n 8  P a ge 2  of 4 6   2  Se pte m ber  2 0 2 0  T A B L E:  S U M M A R Y O F C H A N G E S  
Re visi o n D ate  C h a n ges  
Pri or 
a me n d me nts    Title c orrecte d o n pa ge 1 a n d t hr o u g h o ut  
  Clarifie d S A E re p orti n g g ui da nce f or Pfizer, t he n e w st u d y s p o ns or.  A d de d S CI 
S A E re p orti n g g ui deli nes f or i n vesti gat or -i nitiate d trials i n A p pe n di x B.  
  Clarifie d st u d y  cale n dar –  c ha n ge d st u d y wee ks t o st u d y c ycl es.  
  Clarifie d defi niti o n of c hil d beari n g p ot e ntial o n eli gi bilit y c hec klist a n d i n 
eli gi bilit y criteria secti o n i n pr ot oc ol  
  Clarifie d nee d e d i ma gi n g at baseli ne o n eli gi bilit y c hec klist  
  A d de d t he f oll o wi n g t o e li gi bilit y c hec klist 
o  A vaila bilit y of arc hi val t u m or tiss ue fr o m pri mar y breast/t u m or site  
o  A de q uate fres h or arc hi v al t u m or tiss ue fr o m metastatic bi o ps y site, if bi o ps y 
is tec h nicall y feasi ble 
o  S u bjects of c hil d beari n g p ote ntial m ust be willi n g t o ha ve a d d iti o nal uri ne 
pre g na nc y t ests d uri n g t h e st u d y.  
o  Clarifie d t hat le pt o me ni n geal disease is e x cl u de d  
T he a b o ve c ha n ges were pre vi o usl y re p orte d t o t h e I R B, b ut are retai ne d f or 
ali g n me nt wit h t his versi o n of t he pr ot oc ol, as s u b mitte d t o t he I N D.  
  Eli gi bilit y  Criteria har m o nize d wit h Eli gi bilit y  C h ec klist, a n d prese nt e d as a 
si n gle i nsta nce at Secti o n 3. 1.  
o  U p date d t he refere nce t o N CI C o m m o n Ter mi n ol o g y Criteria f or A d verse 
E ve nts ( C T C A E) versi o n  4 t o versi o n  5 . . 
2  Se pte m ber  2 0 2 0  I n a d vert e ntl y o mitte d te xt is rest ore d 
 
I R B-3 1 9 1 3 versi o n 8  P a ge 3  of 4 6   2  Se pte m ber  2 0 2 0  T A B L E O F C O N T E N T S  
 
I N V E S TI G A T O R S ....................................................................................................................... 1  
P R O T O C O L S Y N O P SI S  ............................................................................................................. 5  
S T U D Y S C H E M A  ........................................................................................................................ 8  
LI S T O F A B B R E VI A TI O N S A N D D E FI NI TI O N O F T E R M S  .............................................. 9  
1. O B J E C TI V E S  ..................................................................................................................... 1 0  
1. 1 PRI M A R Y OBJ E C TI V E  ..................................................................................................... 1 0  
1. 2 SE C O N D A R Y OBJ E C TI V E S  ............................................................................................... 1 0  
1. 3 CO R R E L A TI V E OBJ E C TI V E S  ............................................................................................ 1 0  
2. B A C K G R O U N D  ................................................................................................................. 1 0  
2. 1  B R C A 1/ 2 -M U T A TI O N AS S O CI A T E D BR E A S T CA N C E R  ................................................... 1 0  
2. 2 SP O R A DI C TRI P L E-NE G A TI V E BR E A S T CA N C E R  ............................................................. 1 1  
2. 3 CA N C E R S WI T H GE R M LI N E  O R SO M A TI C DE FI CI E N C Y I N D N A  DO U B L E -ST R A N D RE P AI R
  1 1  
2. 4 TH E MY RI A D HO M O L O G O U S RE C O M B I N A TI O N DE FI CI E N C Y (H R D )  AS S A Y .................. 1 3  
2. 5 OV E R VI E W O F T H E S T U D Y  A G E N T T A L A Z O P A RI B  ............................................................ 1 4  
2. 6 RA TI O N A L E  .................................................................................................................... 1 8  
2. 7 ST U D Y DE SI G N  .............................................................................................................. 2 0  
3. P A R TI CI P A N T S E L E C TI O N A N D E N R O L L M E N T P R O C E D U R E S  ...................... 2 1  
3. 1 ELI GI BI LI Y CRI T E RI A  A N D PA R TI CI P A N T ELI GI BI LI T Y CH E C K LI S T  ... ER R O R ! BO O K M A R K 
N O T D E FI N E D . 
3. 2 IN F O R M E D CO N S E N T PR O C E S S  ....................................................................................... 2 1  
3. 3 RA N D O MI Z A TI O N PR O C E D U R E S  ..................................................................................... 2 6  
3. 4 ST U D Y TI M E LI N E  ........................................................................................................... 2 6  
4. T R E A T M E N T P L A N  ......................................................................................................... 2 6  
4. 1 SC R E E NI N G PR O C E D U R E S  .............................................................................................. 2 6  
4. 2 DO SI N G A N D AD MI NI S T R A TI O N SC H E D U L E  .................................................................... 2 7  
4. 3 PR E-TR E A T M E N T EV A L U A TI O N S  .................................................................................... 2 8  
4. 4 EN D O F TR E A T M E N T PR O C E D U R E S  ................................................................................ 2 8  
4. 5 GE N E R A L CO N C O MI T A N T ME DI C A TI O N A N D SU P P O R TI V E CA R E GUI D E LI N E S  ............... 2 9  
4. 6 DU R A TI O N O F TH E R A P Y A N D FO L L O W -UP ..................................................................... 2 9  
4. 7 CRI T E RI A F O R RE M O V A L F R O M ST U D Y .......................................................................... 2 9  
4. 8 AL T E R N A TI V E S  .............................................................................................................. 2 9  
4. 9 CO M P E N S A TI O N  ............................................................................................................. 3 0  
5. I N V E S TI G A TI O N A L A G E NT/ D E VI C E/ P R O C E D U R E I N F O R M A TI O N  ............... 3 0  
5. 1 IN V E S TI G A TI O N A L AG E N T ............................................................................................. 3 0  
5. 2 PH A R M A C O D Y N A MI C PR O P E R TI E S  ................................................................................. 3 0  
5. 3 PH A R M A C O KI N E TI C PR O P E R TI E S  .................................................................................... 3 1  
5. 4 SU P P LI E R  ....................................................................................................................... 3 1  
5. 5 DO S A G E FO R M ............................................................................................................... 3 1  
5. 6 AG E N T OR D E RI N G A N D PA C K A GI N G  .............................................................................. 3 1  
5. 7 ST O R A G E A N D S H E L F LI F E  .............................................................................................. 3 2  
I R B-3 1 9 1 3 versi o n 8  P a ge 4  of 4 6   2  Se pte m ber  2 0 2 0  5. 8 NA T U R E A N D CO N T E N T S O F CO N T AI N E R  ....................................................................... 3 2  
5. 9 SP E CI A L PR E C A U TI O N S F O R DI S P OS A L A N D OT H E R HA N D LI N G  ..................................... 3 2  
6. D O S E M O DI FI C A TI O N S  ................................................................................................. 3 2  
7. A D V E R S E E V E N T S A N D R E P O R TI N G P R O C E D U R E S  ........................................... 3 3  
7. 1 PO T E N TI A L AD V E R S E EV E N T S  ....................................................................................... 3 3  
7. 2 AD V E R S E EV E N T A N D PR E G N A N C Y RE P O R TI N G  ............................................................ 3 5  
7. 3 PR O D U C T CO M P L A I N T S RE P O R TI N G  ............................................................................... 3 6  
8. C O R R E L A TI V E  S T U DI E S  .............................................................................................. 3 6  
9. S T U D Y C A L E N D A R  ......................................................................................................... 3 8  
1 0. M E A S U R E M E N T S  ........................................................................................................ 3 9  
1 0. 1 PRI M A R Y EN D P OI N T  ...................................................................................................... 3 9  
1 0. 2    SE C O N D A R Y EN D P OI N T S  .................................................................................................. 3 9  
1 0. 3 CO R R E L A TI V E EN D P OI N T S  ............................................................................................. 4 0  
1 1. R E G U L A T O R Y C O N SI D E R A TI O N S  ........................................................................ 4 0  
1 1. 1 IN S TI T U TI O N A L RE VI E W O F PR O T O C O L  .......................................................................... 4 0  
1 1. 2 DA T A A N D SA F E T Y MO NI T O RI N G PL A N ......................................................................... 4 0  
1 1. 3 DA T A MA N A G E M E N T PL A N ........................................................................................... 4 1  
1 2. S T A TI S TI C A L C O N SI D E R A TI O N S  .......................................................................... 4 1  
1 2. 1 AN A L Y TI C PL A N F O R ST U D Y OBJ E C TI V E S  ..................................................................... 4 1  
1 2. 2 AN A L Y SI S P O P U L A TI O N  .................................................................................................. 4 2  
1 2. 3 SA M P L E SI Z E CA L C U L A TI O N S  ........................................................................................ 4 2  
1 2. 4  AC C R U A L ES TI M A T E S A N D FE A SI BI LI T Y  ........................................................................ 4 2  
R E F E R E N C E S  ............................................................................................................................ 4 3  
A P P E N DI X A :  S A E R E P O R TI N G G UI D E L I N E S; S CI S O P 1 0-1 6 -2 0 1 4  ...................... 4 6  
 
I R B-3 1 9 1 3 versi o n 8  P a ge 5  of 4 6   2  Se pte m ber  2 0 2 0  P R O T O C O L S Y N O P SI S  
Title of St u d y:   A p hase  2  cli nical trial of t he P A R P i n hi bit or talaz o parib  i n B R CA 1 a n d B R C A 2 
wil d -t y pe patie nts wit h a d va nce d tri ple-ne gati ve breast ca ncer a n d h o m ol o g o us rec o m bi nati o n 
deficie nc y or  a d va nce d H E R 2 -ne gati ve breast  ca ncer  or ot her s oli d t u m ors  wit h a m utati o n i n 
h o m ol o g o us rec o m bi nati o n pat h wa y ge nes  
C o nce pt a n d R ati o n a le:  I n t his p hase 2  pr o of -of -c o nce pt cli nical trial, we pr o p ose t o test t he 
efficac y of  talaz o pari b, a p ote nt, orall y-bi oa vaila ble P A R P i n hi bit or, wit h a n esta blis he d P hase  2  
rec o m me n de d d ose, i n t he treat me nt of a d va nce d B R C A wil dt y pe ( W T ), H E R 2-n e gati ve  breast 
ca ncer a n d ot her s oli d t u m ors  wit h h o m ol o g o us rec o m bi nati o n ( H R ) deficie nc y.  T he trial is 
c o m p ose d of t w o patie nt c o h orts .  C o h ort  A  c o nsists of patie nts wit h a d va nce d tri ple-ne gati ve 
breast ca ncer ( T N B C ) a n d a hi g h h o m ol o g o us rec o m bi nati o n defici e nc y ( H R D ) sc ore as assesse d 
b y t he M yria d  H R D  assa y.  C o h ort  B  c o nsists of patie nts wit h a d va nce d H E R 2 -ne gati ve breast 
ca ncer or ot her s oli d t u m ors  wit h a ger mli ne  or s o matic m utati o n i n a ge ne li n ke d t o t he  H R 
pat h wa y .  Patie nts alrea d y i de ntifie d as har b ori n g a deleteri o us or s us pecte d deleteri o us ger mli ne  
or s o matic m utati o n i n t he  H R pat h wa y will be i m me diatel y eli gi ble f or treat me nt i n C o h ort  B.  
      T he M yria d  H R D  assa y is a t u m or tiss ue -base d assa y t hat has bee n de vel o pe d usi n g a n 
i n direct a p pr oach t hat all o ws f or t he detecti o n of  H R D  as assesse d b y q ua ntif yi n g le vels of 
ge n o mic i nsta bilit y .  T he Sta nf or d Breast Ca ncer gr o u p has pre vi o usl y assesse d t his assa y i n a 
plati n u m -base d ne oa dj u va nt p hase  2  trial a n d s h o we d t hat a hi g h H R D  sc ore si g nifica ntl y 
c orrelates wit h a fa v ora ble pat h ol o gic res p o nse i n earl y -sta ge T N B C wit h a n d wit h o ut a ger mli ne  
B R C A 1/ 2 m utati o n .  Li ke wise, Isa k off a n d c ollea g ues rece ntl y re p orte d t he c orrelati ve e n d p oi nts 
of t he T B C R C 0 0 9 st u d y, a si n gle -ar m p hase  2  trial of plati n u m t hera p y i n metastatic T N B C.  
W hile esta blis he d bi o mar kers, i ncl u di n g p 6 3/ p 7 3 rati o a n d p 5 3 a n d PI K 3 C A m utati o ns faile d t o 
pre dict f or plati n u m res p o nse,  H R D  assa ys di d i de ntif y s p ora dic T N B C t u m ors t hat were m ore 
res p o nsi ve t o plati n u m t hera p y.  
      A s e parate a p pr oac h t o detecti n g  H R D  ma y be t he use of  m ulti ple x ge ne pa nels t hat e val uate  
n o n -B R C A 1/ 2  ger mli ne  m utati o ns i m plicate d i n h o m ol o g o us rec o m bi nati o n .  M utati o ns i n ge nes 
li n ke d t o t he H R pat h wa y, s uc h as A T M, P A L B 2 a n d R A D 5 1  a m o n g ot hers , are h y p ot hesize d t o 
ha ve si milar c he m ose nsiti vit y t o D N A -da ma gi n g t hera pies as m utati o ns i n B R C A 1 a n d B R C A 2 
gi ve n a si milar s y nt heticall y let hal effect .  I de ntificati o n of s o m atic m utati o ns i n  H R -relate d 
ge nes t hr o u g h c o m merciall y a vaila ble ne xt -ge nerati o n D N A se q ue nci n g of t u m or tiss ues als o has 
p ote ntial t o i de ntif y patie nts w h o ma y deri ve be nefit fr o m D N A re pair defect -tar gete d t hera p y.  
H o we ver, n o st u dies t o -date ha ve directl y e val uate d t he r ole of D N A -da ma gi n g t hera pies i n s uc h 
patie nt p o p ulati o ns.  
P ri m ar y O bjecti ve(s):   
T o deter mi ne w het her si n gle a ge nt talaz o pari b ca n res ult i n a 3 0 % or greater o bjecti ve res p o nse 
i n patie nts wit h a d va nce d s p or a dic tri ple-ne gati ve breast ca ncer wit h h o m ol o g o us rec o m bi nati o n 
deficie nc y as assesse d b y t he  H R D  assa y ( C o h ort  A)  or a d va nce d H E R 2 ne gati ve (ie , T N or 
E R/ P R p ositi ve) breast ca ncer or  ot her  s oli d t u m ors wit h a ger mli ne  or s o m atic m utati o n i n 
t he H R pat h wa y, e xcl u di n g B R C A 1/ 2 ( C o h ort  B).  
Sec o n d ar y O bjecti ve(s):  
1. T o deter mi ne t he cli nical be nefit rate (c o m plete res p o nse, partial res p o nse or sta ble diseas e 
≥  2 4  wee ks)  
2 . T o deter mi ne pr o gressi o n-free s ur vi val 
3 . T o e val uate t he safet y of talaz o pari b i n t his patie nt p o p ulati o n 
C orrel ati ve O bjecti ve(s):  
1. T o c o m pare t he rate of res p o nse i n s u bjects wit h T N B C wit h or wit h o ut a n u n derl yi n g 
I R B-3 1 9 1 3 versi o n 8  P a ge 6  of 4 6   2  Se pte m ber  2 0 2 0  ger mli ne  H R pat h wa y m utati o n (C o h ort  A).  
2. T o c o m pare t he  H R D  sc ores i n res p o n ders vers us n o n-res p o n ders wit h u n derl yi n g deleteri o us 
or s us pecte d deleteri o us ger mli ne  or s o matic  H R ge ne m utati o ns ( C o h ort  B).  
3. T o assess t he c o nc or da nce of t he  H R D  sc ores i n t he pri mar y t u m or tiss ue wit h t hat i n t he 
metastatic t u m or tiss ue.  
4. T o assess i n metastatic t u m or bi o ps y sa m ples, t he R A D 5 1 stat us of t he t u m or at baseli ne 
(a bse nt or prese nt) as a f u ncti o nal rea d o ut of H R ca pacit y a n d c orrelate t his wit h  H R D  a n d 
m utati o nal stat us  
P ri m ar y E n d p oi nt(s):  
T he o bjecti ve res p o nse rate of  talaz o pari b usi n g R E CI S T 1. 1 criteria  
Sec o n d ar y E n d p oi nt(s):   
1. Cli nical be nefit rate  
2 . Pr o gressi o n-free s ur vi val 
3 . Safet y 
C orrel ati ve E n d p oi nt(s):  
1. O bj ecti ve res p o nse rate i n s u bjects wit h T N B C wit h or  wit h o ut a n u n derl yi n g ger mli ne  H R 
pat h wa y m utati o n i n C o h ort  A  
2. C orrelati o n of  H R D  sc ores wit h res p o nse i n s u bj ects  wit h u n derl yi n g  ger mli ne  or s o matic  H R 
ge ne m utati o ns i n C o h ort  B  
3. C orrelati o n of  H R D  sc ores i n t he pri mar y t u m or tiss ue a n d t he metastatic t u m or tiss ue. 
4. C orrelati o n of R A D 5 1 stat us i n t he metastatic t u m or wit h H R D  a n d m utati o nal stat us. 
St u d y Desi g n:  A si n gle -ar m, p hase  2  cli nical trial c o nsisti n g of 2 patie nt c o h orts 
( parallel desi g n), usi n g a n o pti mal t w o -sta ge desi g n.  T he t w o pa tie nt c o h orts are t he f oll o wi n g: 
C o h ort  A:   T N B C patie nts wit h  H R deficie nc y as meas ure d b y t he M yria d  H R D  assa y 
C o h ort  B:   H E R 2 -ne gati ve (ie , tri ple-ne gati ve or estr o ge n/ pr o gester o ne rece pt or -p ositi ve) breast 
ca ncer or ot her s oli d t u m or  patie nts wit h a ge r mli ne or s o m atic m utati o n i n a  H R pat h wa y ge ne .  
Ge ne m utati o ns of i nterest are:  P T E N ;  P A L B 2 ;  C H E K 2 ;  A T M ;  N B N ;  B A R D 1 ;  B RI P 1 ;  
R A D 5 0 ;  R A D 5 1 C ;  R A D 5 1 D ;  M R E 1 1 ;  A T R ;  Fa nc o ni a ne mia c o m ple me ntati o n gr o u p of 
ge nes ( F A N C A ;  F A N C C ;  F A N C D 2 ;  F A N C E ;  F A N C F ;  F A N C G ;  F A N C L).  
N u m ber of P atie nts:  We will accr ue 1 0 patie nts, if we o bser ve a res p o nse i n at least 2 patie nts, 
t he n we will accr ue 10  a d diti o nal patie nts f or a t otal of 2 0  patie nts i n eac h c o h ort , a n d re q uire a 
res p o nse i n at least 3 patie nts o ut of 2 0 t o declare statistical si g nifica nce at a o ne si de d 
si g nifica nce le vel of 5 %, i n or der t o ass ure 8 0 % p o wer.   It is e x pecte d t hat at least 
1 0  H E R 2 -ne gati ve breast ca ncer patie nts will be e nr olle d i n C o h ort  B.  
S u m m ar y of Eli gi bilit y :  
  A d ults wit h a s ol i d t u m or meas ura ble per R E CI S T v 1. 1,  wit h o ut s us pecte d deleteri o us 
ger mli ne B R C A 1 or B R C A 2 ge ne m utati o n i n t he ger mli ne, a n d ha vi n g recei ve d at least 1 
pri or s yste mic t h era p e utic re gi me n.  Eli gi ble s u bjects will ha ve E C O G perf or ma nce 
stat us of 0 t o 2 a n d a de q uate or ga n f u ncti o n, wit h a de q uate birt h c o ntr ol preca uti o ns.  Please 
see c o m plete Eli gi bilit y Criteria at Secti o n 3 . 1.  
I nter ve nti o n a n d M o de of Deli ver y:   T alaz o pari b , 1 m g  P O dail y (c o nti n u o us d osi n g) o n a 
2 8 -da y c ycle.  Patie nts will be e val uate d  pri or t o eac h c ycle.  T his will i ncl u de a cli nical 
e val uati o n, i ncl u di n g safet y assess me nt a n d p h ysical e xa m, as well as la b orat or y assess me nt.  
D ur ati o n of I nter ve nti o n a n d E v al u ati o n:   T he n o mi nal d urati o n of treat me nt is 3 6  c ycles 
I R B-3 1 9 1 3 versi o n 8  P a ge 7  of 4 6   2  Se pte m ber  2 0 2 0  ( 2 8 da ys per c ycle),  b ut C R, P R, or S D patie nts ma y  c o nti n ue t hera p y u ntil e vi de nce of 
pr o gressi ve disease or u nacce pta ble t o xicit y occ urs.  Pr ot oc ol t hera p y will be disc o nti n ue d f or 
pr o gressi ve disease at a n y ti me .  Patie nts are free t o halt t hera p y at t heir re q uest .  Treat m e nt ma y 
be disc o nti n ue d if i nterc urre nt c o -m or bi dities occ ur, w hic h, i n t he o pi ni o n of t he treati n g 
p h ysicia n, w o ul d precl u de safe a d mi nistrati o n of st u d y dr u gs.  
F u n di n g, Re g ul at or y, a n d F e asi bilit y Iss ues:   T his i n vesti gat or -i nitiate d P hase 2  cli nical t rial 
will be f u n de d b y  Pfizer P har mace utical, I nc.  T his p har mace utical c o m pa n y has c o m mitte d t o 
pr o vi di n g t he st u d y dr u g, talaz o pari b.  
P atie nt Acce pt a bilit y/ Et hics a n d C o nse nt Iss ues:   Gi ve n t he lac k of tar gete d t hera p y o pti o ns 
f or T N B C patie nts, we belie ve t his trial will be a welc o me d alter nati ve c o m pare d t o sta n dar d 
c yt ot o xic c he m ot hera p y i n t his patie nt p o p ulati o n.  Of p ossi ble c o ncer n t o t he patie nt or a d v ocate 
c o m m u nit y ma y be t hat we will re q uire t u m or tiss ue of a metastatic site f or trial partici pati o n .  
T his bi o ps y is critical f or t he s uccessf ul c o n d uct of t his st u d y .  F urt her m ore, as patie nts will 
re q uire ge netic testi n g, we will offer ge netic c o u nseli n g t o all patie nts e nr olle d i n t his trial.  
 
I R B-3 1 9 1 3 versi o n 8  P a ge 8  of 4 6   2  Se pte m ber  2 0 2 0  S T U D Y S C H E M A  
 
 
I R B-3 1 9 1 3 versi o n 8  P a ge 9  of 4 6   2  Se pte m ber  2 0 2 0  LI S T O F A B B R E VI A TI O N S A N D D E FI NI T I O N O F T E R M S 
A E  A d verse e ve nt  
A L T  Ala ni ne a mi n otra nsferase  
A N C  A bs ol ute ne utr o p hil c o u nt  
A S T  As partate a mi n otra nsferase  
BI D  T wice dail y  
B S A  B o d y s urface area  
C B C  C o m plete bl o o d c o u nt  
CI  C o nfi de nce i nter val  
C M A X  Ma xi m u m c o nce ntrati o n of dr u g  
C N S  Ce ntral ner v o us s yste m  
C R F  Case re p ort/ Rec or d f or m  
C R  C o m plete res p o nse  
C T C A E  C o m m o n T er mi n ol o g y Criteri a f or A d verse E ve nts  
D L T  D ose Li miti n g T o xicit y  
D S M C  Data Safet y M o nit ori n g C o m mittee  
E C G  Electr ocar di o gra m  
E C O G  Easter n c o o perati ve o nc ol o g y gr o u p  
E R  Estr o ge n rece pt or  
F D A  U S f o o d a n d dr u g a d mi nistrati o n  
F F P E  F or mali n -fi xe d paraffi n e m be d de d 
G C P  G o o d cli nical practice  
H g b  He m o gl o bi n  
HI V  H u ma n I m m u n o deficie nc y Vir us  
H N S T D  Hi g hest n o n -se verel y t o xic d ose 
H R  H o m ol o g o us Rec o m bi nati o n  
H R D  H o m ol o g o us Rec o m bi nati o n Deficie nc y  
I B I n vesti gat or's br oc h ure 
I P I n vesti gati o nal pr o d uct 
I R B I nstit uti o nal Re vie w B oar d 
I V I ntra ve n o us 
L F T  Li ver f u ncti o n test  
L O H  L o ss of heter oz yg osit y  
M T D  Ma xi m u m t olerate d d ose  
O S  O verall s ur vi val  
P A R P  P ol y -A D P ri b o se p ol y merase 
p C R  P at h ol o gic c o m plete res p o nse  
P D  Pr o gressi ve disease d  or P har mac o d y na mic s 
P F S  Pr o gressi o n -free s ur vi val  
P K  P har mac o ki netic  
Plt  Platelet c o u nt  
P R  P artial res p o nse  or Pr o gester o ne rece pt or  
Q D  O nce dail y  
R E CI S T  Res p o nse e val uati o n cr iteria i n s oli d t u m ors 
R R  Res p o nse rate  
S A E  Seri o us a d verse e ve nt  
S D  Sta ble disease  
S R C  Scie ntific Re vie w C o m mittee  
T N  Tri ple -ne gati ve  
T K  T o xic o ki netic  
T N B C  Tri ple -ne gati ve breast ca ncer  
U L N  U p per li mit of n or mal  
W B C  W hite bl o o d cell  
I R B-3 1 9 1 3 versi o n 8  P a ge 1 0  of 4 6   2  Se pte m ber  2 0 2 0  1.   O B J E C TI V E S  
1. 1   Pri m ar y O bjecti ve  
  T o deter mi ne w het her si n gle a ge nt talaz o pari b pr o d uces better t ha n e x pecte d res p o nses  i n 
patie nts wit h a d va nce d  s p or a dic tri ple-ne gati ve breast ca ncer wit h h o m ol o g o us 
rec o m bi nati o n deficie nc y as assess e d b y t he  H R D  assa y (C o h ort  A)  a n d/ or  a d va n ce d 
H E R 2 -ne gati ve ( ie, T N - or E R/ P R -p ositi ve) breast  ca n cer or ot her n o n -breast s oli d 
t u m ors wit h  a ger mli ne  or s o m atic m utati o n i n t he H R pat h wa y , e x cl u di n g B R C A 1 or 
B R C A 2 (C o h ort  B).   
1. 2   Sec o n d ar y O bjecti ves  
1. 2. 1  T o deter mi ne cli nical b e ne fit rate (c o m plete res p o nse, partial res p o ns e or sta ble 
disease ≥  2 4  wee ks)  
1. 2. 2   T o deter mi ne pr o gressi o n -free s ur vi val i n b ot h c o h orts 
1. 2. 3  T o e val uate t he s afet y of talaz o pari b i n b ot h patie nt p o p ulati o n s 
1. 3   C orrel ati v e O bjecti v es  
1. 3. 1  T o c o m pare t h e rate of res p o nse i n s u bjects wit h T N B C wit h or wit h o ut a n 
u n de rl yi n g ger mli ne  H R pat h wa y m utati o n ( C o h ort  A).  
1. 3. 2  T o c o m pare t h e  H R D  sc ores i n res p o n ders vers us n o n-res p o n ders wit h u n derl yi n g 
deleteri o us or s us pecte d deleteri o us ger mli ne  or s o matic  H R ge n e m utati o ns 
(C o h ort  B).  
1. 3. 3  T o assess t he c o n c or da n ce of t he  H R D  sc ores i n t h e pri mar y t u m or tiss ue wit h 
t hat i n t he metastatic t u m or tiss ue. 
1. 3. 4  T o assess i n metastatic t u m or bi o ps y sa m ples, t he R A D 5 1 stat us of t he t u m or at 
baseli ne (a bs e nt or pres e nt) as a f u ncti o nal rea d o ut of  H R ca pacit y a n d c orrelate 
t his wit h  H R D  a n d m utati o nal stat us 
2.   B A C K G R O U N D  
2. 1  B R C A 1/ 2 -M ut ati o n Ass oci ate d Bre ast C a ncer  
Ca ncer is a ge netic dise ase ca use d b y a n acc u m ulati o n of c ha n ges i n t he D N A s e q ue nce o ver 
ti me, ge n erall y i n v ol vi n g t u m or s u p pressor ge nes or pr ot o -o nc o ge n es .1 Cells c o nti n uall y ac q uir e 
D N A da ma ge a n d ha v e r o b ust a n d re d u n d a nt D N A da ma ge re pair mec h a nis ms t hat f u ncti o n t o 
mai n tai n ge n o mic sta bilit y.  D o u ble -stra n d D N A brea ks are e xtre mel y c yt ot o xic a n d t heir re pair 
via  n o n -h o m ol o g o us e n d j oi ni n g a n d h o m ol o g o us rec o m bi nati o n are criticall y i m p orta nt .  
E x cisi o n re pair pat h wa ys, i ncl u di n g base e x cisi o n re pair, n ucle oti de e x cisi o n re pair a n d 
mis matc h re pair, als o pla y i m p orta nt r oles i n rest ori n g t he n or mal D N A s e q ue nce.  
Breast ca ncers t hat arise i n B R C A 1 a n d B R C A 2 m utati o n carriers are c haract erize d b y 
h o m ol o g o us rec o m bi nati o n D N A re pair defici e n c y d ue t o l oss of t he f u ncti o ni n g w il d-t y p e 
B R C A 1 or B R C A 2 allele .  T he B R C A 1 a n d B R C A 2 ge n e pr o d ucts are critical f or D N A 
d o u ble -stra n d brea k re p air via h o m ol o g o us rec o m bi nati o n.1  P ol y ( A D P -ri b ose) p ol y merase-1 
( P A R P 1) a n d P A R P 2 are n uclear e nz y mes cr ucial f or recr uit me nt of a cell's base e x cisi o n re pair 
mac hi ner y t o sites of D N A da ma ge .  It h as b ee n esta blis he d t hat P A R P 1/ 2 i n hi bit ors ca n ca use 
selecti ve c yt ot o xicit y i n cell li nes m uta nt f or B R C A 1 or B R C A 2, d ue t o stalli n g of re plicati o n 
I R B-3 1 9 1 3 versi o n 8  P a ge 1 1  of 4 6   2  Se pte m ber  2 0 2 0  f or ks i n d uce d b y a bse n ce of P A R P e nz y me a n d s u bse q ue nt s h utti n g of t he D N A da ma ge t o 
d o u blestra n d brea ks .  Wit h c o nc urre nt l oss of h o m ol o g o us rec o m bi nati o n -de pe n de n t D N A 
d o u ble -stra n d brea k re pair, t his lea ds t o a s y nt h eticall y let hal i nteracti o n .2 -7   
2. 2   S p or a dic Tri ple -Ne g ati ve Bre ast C a ncer   
F or s o me ti me, it has bee n a p preciate d t hat t he maj orit y of i n vasi ve breast ca nce rs t hat de v el o p 
i n w o me n wit h deleteri o us B R C A 1 ger mli ne  m utati o ns are tri ple -ne gati ve,8, 9 defi ne d 
pat h ol o gicall y as lac ki n g e x pressi o n of t he estr o ge n a n d pr o gester o ne rece pt ors ( E R/ P R) wit h n o 
a m plificati o n of t h e H E R 2/ ne u o nc o ge ne ,1 0 a n d t his has pr o vi de d fasci nati n g mec h a nistic cl ues 
t o u n derl yi n g t u m or bi ol o g y a n d p ossi ble t hera pe utic tar gets.  Base d o n si milarities bet wee n 
s p ora dic tri ple-n e gati ve breast ca ncer a n d B R C A 1 -deficie nt breast ca n cer a n d t he k n o w n r ole of 
B R C A 1 i n D N A re pair, t he h y p ot hesis h as e mer ge d t hat s p ora d ic tri ple-ne gati ve  breast t u m ors 
ma y p ossess si milar D N A re p air d efects a n d de m o nstrate si milar c h e m ose nsiti vit y as B R C A 1 
m utati o n -ass ociate d breast  t u m ors.  Pre -cli nicall y, tri ple-ne gati ve  breast ca ncer cell li nes, li k e 
B R C A 1 -defi cie nt ca ncer cell li nes, de m o nstrat e i ncrea se d se nsiti vit y t o P A R P i n hi bito rs, 
cis plati n a n d ge mcita bi n e.1 1  A d diti o nall y, t hese ce ll li nes are m ore se nsiti ve t o o xi dati ve D N A 
da ma ge c o m pare d t o l u mi nal breast t u m or cells or n or mal breast e pit heli al cells a n d h a ve b ee n 
s h o w n t o be deficie nt i n base e x cisi o n re pair.1 2  
T he acti vit y of ola pari b,  a b o na fi de P A R P i n hi bit or, was i n vesti gate d i n a s mall c o h ort of 
u nselecte d s p ora dic tri pl e -ne gati ve breast ca n cer patie nts, h o we ver, n o o bjecti ve res p o ns es were 
n ote d a n d f u rt her de vel o p me nt was halte d.1 3  U nf or t u natel y, t his e x perie n ce t h warte d t he cli nical 
pr o gress of P A R P i n hi bit ors i n s p ora dic tri ple -n e gati ve breast ca n cer.  T he i na bilit y t o select 
B R C A 1/ 2 wil d -t y p e t u m ors wit h u n derl yi n g D N A re pair defects f urt her c o m p o u n de d t he 
pr o ble m .  D ue t o t hese earl y c halle n ges, t he r ole of P A R P i n hi biti o n i n t he treat me nt of s p ora di c 
tri ple-ne gati ve breast c a n cer has re mai ne d u n d efi n e d.  
2. 3   C a ncers wit h Ger mli ne  or S o m atic Deficie nc y i n D N A D o u ble -Str a n d Re p air  
I n t he past year, tar get e d ge n e p a nels h a ve arise n t hat e val u ate ger mli ne  m utati o ns i n D N A re p air 
pat h wa ys i m plicate d i n ca ncer de vel o p me nt a n d pr o gressi o n .  M utati o ns i n ge nes li n ke d t o 
c hec k p oi nt c o ntr ol a n d re g ulati o n of t he D N A -d o u ble stra n d brea k re p air pat h wa y, s uc h as 
A T M, P A L B 2 a n d R A D 5 1 are h y p ot hesiz e d t o h a ve si milar c he m os e nsiti vit y t o D N A -da ma gi n g 
t hera pies, s uc h as P A R P i n hi bit ors, as m utati o ns i n B R C A 1 a n d B R C A 2 gi ve n a si milar 
s y nt heticall y l et hal effect.  H o we ver, n o st u dies t o date h a ve dir ectl y e val uate d t h e r ole of 
D N A -da m a gi n g t hera pies i n s uc h patie nt p o p ulati o ns, i n part d ue t o a lac k of c o m merciall y 
a vaila ble m ulti ple x ge ne pa nels usi n g n e xt ge nerati o n D N A se q ue nci n g u ntil rece ntl y as well as 
t he l o w pre vale nce of s uc h m utati o ns i n t he ge neral p o p ulati o n. 
I n a Fre nc h st u d y p u blis he d t his year, ne xt -ge nerati o n -seq ue n ci n g -base d s cree ni n g i n 
7 0 8  patie nts wit h eit her a pers o nal hist or y of breast or o varia n ca n cer at a y o u n g a ge, male breast 
ca ncer, or str o n g fa mil y hist or y d e m o nstrate d a n o verall m utati o nal rate of B R C A 1 a n d B R C A 2 
of 1 0. 8 % .  In a d diti o n, 1 0 i nacti vati n g m utati o ns were f o u n d i n P A L B 2 a n d R A D 5 1 C a n d 
1 0  i nacti vati n g m utati o ns f o u n d i n C H E K 2 a n d A T M, wit h a c ollecti ve c o ntri b uti o n esti mate d t o 
be at least 3 % (s ee fi g ure).1 4 
I R B-3 1 9 1 3 versi o n 8  P a ge 1 2  of 4 6   2  Se pte m ber  2 0 2 0   
Fi g ure 1.  Cas tera L, et al .  E ur o pea n J o ur nal of H u ma n Ge netics, J a n uar y 2 0 1 4. 
T he m y Ris k ge ne p a nel de vel o pe d b y M yria d Ge netics similarl y e val u ates a set of 2 5 ca ncer 
s usce pti bilit y ge nes i m plicate d i n here ditar y breast a n d o varia n ca n cer b y ne xt ge n erati o n 
se q ue nci ng .  In  an  a bstract pres e nte d at t he 2 0 1 3 Sa n A nt o ni o Breast Ca n cer S y m p osi u m , 1 9 5 5 
pr os pecti vel y accr ue d patie nt cases (e x cl u di n g p atie nts of As h ke n azi J e wis h herita ge t o 
deter mi ne rel ati ve pre vale nce i n t he ge neral p o p ulati o n) were teste d, a n d de m o nstrate d t hat 
2 7 5  ( 1 4. 0 7 %) were m utati o n carriers i n at least o ne of t he 2 5 ge nes .  I nteresti n gl y, 1 8 2 ( 9. 3 %) of 
patie nts ha d a m utati o n i n B R C A 1 or B R C A 2, w hile 9 6  ( 4. 9 1 %) of patie nts ha d a m utati o n i n 
ot her ge nes, i n cl u di n g A T M, C H E K 2, N B N, a n d P A L B 2 .  1 7 3 8 o ut  of t he 1 9 5 5 patie nts i n t he 
st u d y ha d a pers o nal hist or y of breast ca ncer, wit h 6 3 % dia g n ose d pri or t o t he a ge of 5 0, a n d 
3 7 % at or after t he a ge 5 0.  N ota bl y 1 9 0 2 ( 9 7. 2 9 %) patie nts ha d a varia nt of u ncertai n 
si g nifica n ce i n at least o ne of t he ge n es teste d a n d a n a vera ge of t hree v aria nts was f o u n d per 
patie nt.1 5  
I n a d diti o n t o breast ca ncer, h o m ol o g o us rec o m bi nati o n pat h wa y m utati o ns ha ve bee n i m plicate d 
i n m ulti ple ot her s oli d t u m ors i ncl u di n g o varia n, pr ostate, pa n creas, a n d gastri c ca n cers a m o n g 
ot hers a n d are p ost ulate d t o res ult i n a ‘ B R C A ness’ p he n ot y p e .  F or e x a m ple, a rece nt st u d y has 
s h o w n t hat ger mli ne  m utati o ns i n D N A -re pair ge nes ca n be detecte d i n a p pr o xi matel y 1 0 % of 
patie nts wit h metastatic pr ostate ca ncer.2 8  Of patie nts wit h i de ntifie d m utati o ns, B R C A 2  
m utati o ns c o m prise d 4 4 % of t otal m utati o ns.  Ot her m utati o ns i de ntifie d i ncl u de d A T M  i n 1 3 %, 
C H E K 2  i n 1 2 %, B R C A 1  i n 7 %, R A D 5 1 D  i n 4 %, a n d P A L B 2  i n 4 %.  T hese data pr o vi d e str o n g 
I R B-3 1 9 1 3 versi o n 8  P a ge 1 3  of 4 6   2  Se pte m ber  2 0 2 0  rati o nale f or t he use of P A R P i n hi bit ors i n s oli d t u m ors wit h h o m ol o g o us re pair defi cie nc y 
o utsi de of B R C A 1/ 2  m utati o ns i n t u m ors ot her t ha n breast c a ncer.  
F urt her m ore, i de ntificati o n of s o matic m utati o ns i n  H R -relate d ge nes t hr o u g h c o m merciall y 
a vaila ble ne xt ge nerati o n se q ue nci n g of t u m or tiss ues als o has p ote ntial t o i de ntif y p atie nts wit h 
s o matic D N A re pair alterati o n w h o ma y d eri ve p ote ntial be nefit fr o m D N A defect -t ar gete d 
t hera p y, s uc h as a P A R P i n hi bit or.  St u dies t o assess t he efficac y of t his a p pr oac h are c urre ntl y 
n ot a vaila ble.   
2 . 4  T he M yri a d H o m ol o g o us Rec o m bi n ati o n Deficie nc y ( H R D ) Ass a y  
T he M yria d H o m ol o g o us Rec o m bi nati o n Defici e n c y ( H R D ) Assa y is a n o v el assa y t hat h as bee n 
de vel o pe d usi n g a n i n direct a p pr oac h t hat all o ws f or t he d etecti o n of  H R D  re gar dless of its 
eti ol o g y or  mec ha nis m as meas ure d b y le vels of ge n o mic i nsta bilit y .  T he assa y is c o m pati ble 
wit h f or mali n -fi x e d paraffi n-e m be d de d ( F F P E) t u m or tiss ue a n d B R C A 1 a n d B R C A 2 t u m or 
se q ue nce d ata is si m ulta ne o usl y ge nerate d.  Earl y i n assa y d e vel o p me nt, ge n o mic re gi o ns of  l oss 
of heter oz y g osit y ( L O H) of i nter me diate le n gt h ( >  1 5  M b a n d <  1  c hr o m os o me) were s h o w n t o 
be hi g hl y ass o ciate d wit h  H R deficie nc y a n d t he  H R D -L O H sc ore was deri ve d as a c o u nt of 
L O H re gi o ns of t his le n gt h acr oss t he t u m or ge n o me .1 6  
O ur gr o u p has pre vi o usl y ass esse d t he  H R D -L O H  assa y i n Pr E C O G 0 1 0 5,  a ne oa dj u v a nt trial 
t hat e x pl ore d a n o n-a nt hrac ycli ne, n o n -t a x a ne, plati n u m-base d re gi me n i n patie nts wit h 
tri ple-ne gati ve or B R C A 1/ 2 m utati o n -ass ociate d breast ca ncer .  We  s h o we d t hat a hi g h H R D  
sc ore si g nifica ntl y c orrel ates wit h fa v ora ble pat h ol o gic res p o nse t o a plati n u m -base d re gi me n i n 
earl y-sta ge tri ple-n e gati v e  a n d B R C A 1 or B R C A 2 m utati o n -ass ociate d breast ca ncer1 7 I n t his 
st u d y, patie nts recei ve d car b o plati n A U C 2 a n d ge m cita bi ne 1 0 0 0  m g / m2 o n da ys 1 a n d 8 e ver y 
2 1  da ys i n a d diti o n t o i ni pari b o n da ys 1, 4, 8, a n d 1 1.1 8, 1 9 T he o verall p C R rate i n t he 
i nte nt-t o-treat p o p ulati o n was 3 6 % ( 9 0 % CI:  2 7 -4 6 %) .  N ota bl y, B R C A 1 a n d B R C A 2 m utati o n 
stat us was c o m pre he nsi v el y ass esse d a n d T N B C patie nts wit h a ger mli ne  B R C A 1 or B R C A 2 
m utati o n ac hie ve d a hi g her rate of p C R ( 5 6 %)  c o m pare d t o patie nts w h o were B R C A 1 a n d 
B R C A 2 wil d -t y pe ( 3 3 %).1 8, 1 9  A maj or ai m of Pr E C O G 0 1 0 5 was t o e val uate bi o mar kers of 
res p o nse t o t his ne o a dj u v a nt t hera p y i n patie nts wit h s p ora dic T N B C.  T h e  H R D  assa y s c ore was 
assesse d i n a c o h ort of 7 7 t u m ors i n Pr E C O G 0 1 0 5 w here p at h ol o gic res p o nse was ass esse d 
usi n g t he resi d ual ca ncer b ur de n ( R C B) i n de x.1 7, 2 0  T he a vera ge  H R D  assa y sc ore f or res p o n ders 
was 1 6. 2 a n d t he a vera ge sc ore f or n o n -res p o n ders 1 1. 2 ( p =  0. 0 0 0 3)  usi n g t he  H R D -L O H assa y .  
I nteresti n gl y, n o differen ce i n me dia n  H R D  sc ores was  n ote d bet wee n B R C A 1/ 2 -deficie nt vers us 
B R C A 1/ 2 -pr oficie nt res p o n ders .  F urt her m or e, if B R C A 1/ 2 -deficie nt sa m ples were e x cl u de d 
( n =  5 8), t he ass ociati o n bet wee n res p o ns e t o treat me nt a n d  H R D  assa y sc ore re mai n e d 
si g nifica nt ( p =  0. 0 0 0 6) .  O verall, 7 0 % of pati e nts wit h a n  H R D  assa y sc ore of   1 0 or a 
deleteri o us B R C A 1/ 2 m utati o n res p o n d e d c o m pare d wit h 1 2 % of p atie nts wit h a n  H R D  assa y 
sc ore of <  1 0 a n d i ntact B R C A 1/ 2 stat us ( p  =  0. 0 0 0 0 2).1 7 T hese data s u g gest t hat t u m or 
meas ures of L O H ma y be i m p orta nt bi o mar kers i n t he i de ntificati o n of ger mli ne  B R C A 1 a n d 
B R C A 2 wil d -t y pe p atie nts w h o ma y be n efit fr o m D N A defect-tar get e d t hera p y, s uc h as plati n u m 
or a P A R P i n hi bit or.  
A d diti o nall y, t he  H R D -L O H  assa y h as bee n vali d ate d i n t w o pr os pecti ve b reast ca n cer c o h orts.  
T he Cis plati n -1 c o h ort i ncl u de d 2 8, mai nl y s p ora dic, tri ple -n e gati ve breast ca ncer patie nts 
treate d wit h ne oa dj u va nt cis plati n, 7 5 m g / m2 e ver y 2 1 da ys f or 4 c ycles .  T he Cis plati n -2 c o h ort 
i ncl u de d 5 1 tri ple-n e gati ve breast ca ncer pa tie nts treate d wit h ne o a dj u va nt cis plati n 7 5 m g / m2 
I R B-3 1 9 1 3 versi o n 8  P a ge 1 4  of 4 6   2  Se pte m ber  2 0 2 0  e ver y 2 1 da ys f or 4 c ycl es pl us be vaciz u ma b 1 5  m g / k g f or 3 c ycl es.  T he pat h ol o gic res p o nse i n 
t hese st u dies was assesse d b y t he Miller-Pa y n e ( M P) sc ore, wit h res p o n ders ha vi n g a M P sc ore 
of 4 or 5, a n d n o n -res p o n ders M P sc ores of 1 t o 3 .  A nal yses were als o perf or me d i n patie nts 
ac hie vi n g a p C R vers us n o p C R .  T he a nal ysis of  H R D  sc ore vers us pat h ol o gic res p o ns e was 
perf or me d o n t he c o m bi ne d dataset .  T he mea n  H R D  sc ore a m o n g res p o n ders ( M P 4-5) vers us 
n o n -res p o n ders ( M P 1-3) was 1 8. 0 vers us 1 2. 9 wit h a n o d ds rati o of 3. 6 ( 3. 2 -4. 0) a n d p -v al ue of 
0. 0 1 3 .  Mea n  H R D  sc ores a m o n g patie nts wit h a p C R vers us n o n-p C R was 2 0. 6 vers us 1 3. 4 wit h 
a n o d ds rati o of 7. 4 ( 6. 3 -8. 6) a n d a p -v al ue of 0. 0 0 4 8 .  I m p orta ntl y, a mo n g patie nts wit h a n  H R D  
sc ore <  1 0, n o patie nts ac hie ve d a p C R w hile 2 4 % of patie nts wit h a n  H R D  ≥  1 0 ac hie ve d a p C R 
res ulti n g i n 1 0 0 % se nsiti vit y a n d 1 0 0 % ne gati ve pre dicti ve v al ue f or p C R.  I n t his c o m bi ne d 
c o h ort, 7 2 % of patie nts ha d a n  H R D  sc ore of 1 0 or great er. 
Rece ntl y, t he  H R D  ass a y h as bee n f urt her o pti mize d a n d c urre ntl y i n c or p orat es a d diti o nal 
meas ures of ge n o mic i nsta bilit y, i ncl u di n g tel o meric allelic i m bala nce ( T AI; t he n u m ber of 
re gi o ns wit h allelic i m bala nce t hat e xte n d t o t he s u btel o mere, b ut d o n ot cr oss t he ce ntr o mere) 
a n d lar ge-scale state tra nsiti o ns ( L S T; t he n u m ber of c hr o m os o mal  brea ks bet wee n a djace nt 
ge n o mic re gi o ns l o n ger t ha n 1 0 M b after filteri n g o ut re gi o ns s h orter t ha n 3 M b).2 1, 2 2 T he  H R D  
sc ore is c urre ntl y calc ul ate d b y a d di n g t he L O H, T AI a n d L S T s c ores a n d is re p orte d as a 
c o ntin u o us sc ore fr o m 0 -1 0 0 .  A n  H R D  sc ore of <  4 1 ( pre vi o usl y <  1 0) is defi ne d as  H R 
pr oficie nt a n d  H R D  s c ore of ≥  4 2 ( pre vi o usl y ≥  1 0) as  H R -deficie nt .  Usi n g t his c ut off, ~ 4 8 % of 
T N B C patie nts are classifie d as  H R -deficie nt.  
2. 5   O ver vie w of t he st u d y a ge nt t al az o p ari b 
2. 5 . 1 N o ncli nic al St u dies of t al az o p ari b 
Talaz o pari b  is a hi g hl y p ote nt a n d s pecific i n hi bit or of P A R P 1 a n d 2 wit h acti vit y i n t u m or cell 
li nes beari n g D N A re p air deficie ncies.2 3, 2 4 talaz o pari b i n hi bits P A R P i n vitr o at a l o wer 
c o nce ntr ati o n (I C 5 0  =  0. 5 7  n M ) t ha n A B T 8 8 8 (I C 5 0 =  4. 7 3  n M ), A G 1 4 4 4 7 (I C 5 0 =  1. 9 8  n M ), 
or ola pari b (I C 5 0  =  1. 9 4  n M ).  Talaz o pari b  als o e x ert s si n gle-a ge nt s y nt hetic let halit y of B R C A 
1 a n d 2 a n d P T E N deficie nt cell li nes .  I n B R CA 2 ne gati ve Ca pa n 1 -cells, talaz o pari b was m ore 
p ote nt as si n gle a ge nt t ha n A B T -8 8 8 ( 1 0, 0 0 0 ti mes), A G 1 4 4 4 7 ( 6 0 9 ti mes) a n d ola pari b 
( 2 5 9 ti mes) i n i n hi biti n g P A R P acti vit y.  I n a ni mal m o dels, p ote nt a nti-t u m or acti vit y was 
o bser ve d at oral dail y d oses <  1  m g / k g/ da y.  C o m plete s u p pressi o n of B R C A 1 -deficie nt t u m or 
gr o wt h i n t he M X 1 m o d el was ac hie ve d i n a 3 -m o nt h st u d y w he n d os e d at 0. 1 6 5  m g / k g BI D .2 4 
Si milarl y, s u p pressi o n of P T E N -deficie nt t u m or gr o w t h was ac hie ve d i n x e n otra ns pla nt 
e x peri me nts wit h talaz o pari b d ose d at 0. 3 3  m g / k g o nce dail y f or 2 8 c o nsec uti ve da ys.2 4  
T he oral bi oa vaila bilit y, calc ulate d fr o m t he rati o of t he area u n d er t he c o n ce ntrati o n -ti me c ur ve 
( A U C) f oll o wi n g oral a d mi nistrati o n relati v e t o t he A U C f ollo wi n g i ntra v e n o us (I V) 
a d mi nistrati o n ( A U C oral/ A U C I V), was >  4 2. 7 % i n rats a n d >  5 0. 5 % i n d o gs base d o n si n gle d ose 
c o m paris o ns .  T he c o m p o u n d was meta b oli call y sta ble.  T he ter mi nal half -life of talaz o pari b at 
vari o us d oses i n rats a n d d o gs ra n ges fr o m 2 8 . 5 t o 3 2. 0 hr  a n d 6 9. 7 t o 9 1. 2  hr , res pecti vel y, 
w hic h all o ws f or o nce dail y d osi n g.  
P har mac o ki netic st u dies ha ve b ee n p erf or me d i n rats a n d d o gs .  Stea d y st ate c o n ce ntrati o ns were 
reac h e d o n Da y  1 5 i n rats a n d o n Da y  2 0 i n d o gs usi n g dail y a d mi nistrati o n  of talaz o pari b.  
C o m pari n g Da y  1 5 a n d 2 8 wit h Da y  1 f or all d ose le vels i n d o gs, A U C a n d C ma x i ncrease d fr o m 
Da y  1 t o Da y  1 5 t o Da y  2 8.  
I R B-3 1 9 1 3 versi o n 8  P a ge 1 5  of 4 6   2  Se pte m ber  2 0 2 0  Fi ve -da y re peat d ose t o xicit y a n d t o xic o ki netic ( T K) st u dies wit h 2 8 -da y rec o ver y were 
c o n d ucte d i n rats a n d d o gs .  I n d o gs (t h e m ost se nsiti ve s pecies), talaz o pari b was a d mi nistere d at 
d ose l e vels of 0. 0 0 3, 0. 0 1, 0. 0 3, 0. 1  m g / k g/ da y o ver 5 c o nsec uti ve da ys.  Se vere pa n c yt o p e nia 
was o bser ve d i n d o gs tr eate d wit h t he t w o hi g h est d ose gr o u ps ( 0. 0 3 a n d 0. 1  m g / k g/ da y).  At 
t hese d oses, t he m ea n ( or me dia n) retic ul oc yte na dir occ urre d o n Da y  6 a n d t he platel et a n d 
W B C na dirs o n Da y  1 1.  T hese c h a n ges were re v erse d i n t he gr o u p tr eate d at 0. 0 3  m g / k g/ da y o n 
da ys  1 7  t o 1 8 ( ie, 1 2  t o 1 3 da ys after t he last d ose of t he dr u g) .  M ortal ities occ urre d i n a ni mals 
gi ve n 0. 1  m g / k g/ da y d ue t o bact erial s e ptice mia s ec o n dar y t o b o n e marr o w h y p ocell ularit y a n d 
l y m p h oi d or ga n de pleti o n o n Da y  1 2  t o 1 3 .  C oa g ul ati o n para meters were u naffecte d .  After 
re peat-d ose a d mi nistrati o n of dail y oral tal az opari b  i n d o gs f or 5-da ys, t he hi g h est n o n -se v erel y 
t o xic d ose ( H N S T D) was 0. 0 3 m g / k g/ da y.  T we nt y -ei g ht d a y re p eat d ose t o xicit y a n d T K st u dies 
wit h 2 8 -da y rec o v er y were als o c o n d u cte d i n rats a n d d o gs .  I n d o gs, talaz o pari b was 
a d mi nistere d at d osa ge le ve ls of 0. 0 0 0 5, 0. 0 0 1 5, 0. 0 0 5, 0. 0 1 m g / k g/ da y o ver 2 8 c o nsec uti ve 
da ys .  Tal az o pari b -rel ate d si g ns i ncl u de d he mat ol o g y fi n di n gs i n males a n d fe males gi ve n 0. 0 0 5 
or 0. 0 1  m g / k g/ da y s uc h as mil dl y l o w er re d cell mass, mil dl y t o m o derat el y l o wer platelet a n d 
a bsol ute retic ul oc yte c o u nts, a n d mi ni mall y t o mil dl y l o wer w hite bl o o d cell c o u nts wit h a 
ge n eralize d d ecrease i n all le u k oc yt es .  All of t hese si g ns re verse d or were re versi n g b y t he e n d 
of t he rec o v er y p h ase .  After re peat -d ose a d mi nistrati o n of dail y oral  talaz o pari b i n d o g f or 2 8 
da ys, t he H N S T D was 0. 0 1  m g / k g/ da y. 
I n c o n cl usi o n, t he mai n n o ncli nical fi n di n gs of earl y he m at ol o gical c ha n ges, a n d s u bse q ue nt 
b o ne marr o w a n d l y m p h oi d or ga n d e pleti o n as well as f ocal n ecr osis after re p eat a d mi nistrati o n 
of talaz o pari b are i n acc or da nce wit h t he mec ha nis m of acti o n a n d t he e x p os ure/ distri b uti o n 
patter n .  T hese fi n di n gs were re versi ble a n d t he decrease d retic ul oc yte, platelet, re d bl o o d cell 
( R B C) a n d W B C c o u nts were s e nsiti ve a n d earl y mar kers of tar get or ga n t oxicit y .  Decreases i n 
he mat ol o g y p ara meters were us e d t o cli nicall y m o nit or safet y .  A starti n g cli nical d ose was 
esti mate d usi n g t h e d o g H N S T D as t he d o g was m ore se nsiti ve t o tal az o pari b-rel ate d pri mar y 
t o xicities t ha n t he rat.  Base d o n a 6 ti mes safet y  fact or relati ve t o t he 2 8-da y t o xicit y st u d y i n 
d o g H N S T D, t he esti mat e d safe cli nical starti n g d ose is 1  μ g / k g/ da y.  T h e differe n ce i n relati ve 
bi oa vaila bilit y after a d mi nistrati o n of t he ca ps ule a n d oral ga va ge s us pe nsi o n of talaz o pari b was 
a p pr o xi matel y t w o -f ol d.  Ta ki n g i nt o acc o u nt t he relati ve c ha n ge i n e x p os ure wit h t he ca ps ul e 
vers us t he oral ga v a ge s us pe nsi o n, t he esti mate d safe cli nical starti n g d os e was recalc ulate d a n d 
is 0. 5 μ g / k g/ da y t alaz o pari b.  T heref ore, t he sta rti n g fi x e d cli nical d os e of 2 5 μ g  talaz o pari b i n a 
ca ps ule f or m c orres p o n ds t o 0. 4 2  μ g / k g/da y f or a 6 0 -k g a d ult.  
2. 5 . 2 Cli nic al St u dies of T al az o p ari b   
T hree st u dies o n g oi n g  at t he ti me of t his u p date : 
  P R P -0 0 1, i nitiate d o n J a n uar y 3r d 2 0 1 1, is a si n gl e -ar m, o pe n -la bel st u d y t o assess t h e safet y, 
p har mac o ki netics ( P K), p har mac o d y n a mics ( P D), a n d preli mi nar y efficac y of talaz o pari b i n 
patie nts wit h a d va nce d t u m ors wit h D N A -re pair pat h wa y a b n or malities, partic ularl y t h ose 
ass ociate d wit h B R C A - a n d P T E N-d ysf u ncti o n .  T he i nitial c o h or t of patie nts was treate d 
wit h 2 5  µ g talaz o pari b o nce dail y .  T his t w o -sta ge p h ase  1  st u d y was u p date d at t he 2 0 1 4 
A S C O A n n ual Meeti n g .  At t his ti me e x pa nsi o n p hase e nr oll me nt i n s mall cell l u n g ca ncer, 
ger mli ne  B R C A breast a n d o varia n ca n cer a n d E wi n g's sarc o ma is c o m plete.  T he M T D a n d 
Rec o m me n de d P has e 2 D ose ( R P 2 D) was esta blis he d at 1  m g / d i n 3 9 pts ( 3 3 F/ 6 M) tr eate d at 
d oses ra n gi n g fr o m 2 5 t o 1 1 0 0  μ g / d.  D ose -li miti n g t hr o m b oc yt o p e nia occ urre d i n 1/ 6 a n d 
2/ 5 pts at 9 0 0 a n d 1 1 0 0  μ g / d, res p ecti vel y2 5. 
I R B-3 1 9 1 3 versi o n 8  P a ge 1 6  of 4 6   2  Se pte m ber  2 0 2 0    6 7 3 -3 0 1, i nitiate d o n Oct o ber 3 0,  2 0 1 3 is a n o pe n -la bel, ra n d o mize d, parallel, 2-ar m st u d y of 
talaz o parib  vers us pr ot oc ol -s pecific p h ysicia n's c h oice t hera p y i n s u bjects wit h ger mli ne  
B R C A m utati o n  wit h  l ocall y a d v a nce d a n d/ or met astatic breast ca ncer.  
  6 7 3 -2 0 1: 2 -sta ge, 2-c o h ort p hase  2 trial is t o e val uate t he safet y a n d efficac y of talaz o pari b i n 
s u bjects wit h l ocall y a d v a nce d or m etastatic breast ca ncer wit h a deleteri o us ger mli ne  B R C A 
1 or B R C A 2 m utati o n .  S u bjects will be assi g ne d t o eit her C o h ort  1 or 2 base d o n pri or 
c he m ot hera p y f or metast atic disease:  
  C o h ort  1) S u bjects w h o ha ve pre vi o usl y res p o n d e d t o plati n u m -c o ntai ni n g re gi me n f or 
metastatic diseas e wit h disease pr o gressi o n >  8 wee ks f oll o wi n g t he last d ose of 
plati n u m; or  
  C o h ort  2) S u bjects w h o ha ve recei ve d >  2 c h e m ot hera p y re gi me ns a n d w h o ha ve ha d n o 
pri or plati n u m t hera p y f or metastatic dise as e  
I n a d diti o n, a f o o d effect st u d y ( 6 7 3-1 0 3) i n 1 8 healt h y v ol u nteers has bee n c o m plete d .  T he f o o d 
effect st u d y s h o w e d t hat, w hile a hi g h -fat, hi g h-cal orie meal del a ye d t he a bs or pti o n of orall y 
a d mi nistere d talaz o pari b, it di d n ot affect t he o v erall e xte nt of a bs or pti o n .  Si n gle 5 0 0 µ g d os es 
were s afe a n d well t olerate d i n healt h y m ale v ol u nteers.  
Preli mi nar y P K data fr o m Part 1 of P R P -0 0 1, t hr o u g h C ycle 1, was a v aila ble at t he ti me of t his 
re p ort.  O verall, plas ma c o nce ntrati o ns of t alaz o pari b i ncrease d i n a d ose-de pe n d e nt ma n ner, 
wit h m ost patie nts o btai ni n g ste a d y -state plas ma c o nce ntrati o ns b y t he e n d of t he s ec o n d wee k of 
dail y d osi n g ( Da y  2 2) .  As i n dicate d b y l o g -li near c o n ce ntrati o n-ti me pr ofiles o n Da y  1 a n d 
Da y  3 5, talaz o pari b eli mi nati o n a p pear e d t o f oll o w bi p hasic ki netics.  
C u m ulati vel y, t here h a v e bee n 1 1 1 S A Es re p orte d i n cli nical st u dies wit h talaz o pari b as of 
N o ve m ber 3 0 t h 2 0 1 3.  T he m ost c o m m o n reas o ns f or S A Es ha ve bee n i nfecti o us ( 3 3 e ve nts), 
gastr oi ntesti nal dis or d ers ( 1 6 e v e nts), bl o o d  a n d l y m p hatic dis or ders ( 1 3 e ve nts), a n d res pir at or y 
dis or ders ( 1 2 e ve nts) .  T he m ost c o m m o nl y re p orte d S A Es b y preferre d ter m i ncl u de fe brile 
ne utr o pe nia ( 9 e ve nts), ne utr o pe nic s e psis ( 7 e ve nts), as cites  ( 5 e ve nts), a n d bactere mia ( 5 
e ve nts).  All b ut 9  of t hese 1 1 1 S A Es were assesse d b y t he i n vesti gat ors as n ot relate d t o 
treat me nt wit h talaz o pari b. 
A d verse e v e nts occ urri n g i n at least 1 0 % of patie nts i n t he p o ole d st u d y p o p ulati o n of P R P -0 0 1, 
P R P -0 0 2, 6 7 3 -1 0 3 a n d 6 7 3 -3 0 1 ha ve i ncl u de d: fati g ue, na usea,  a n e mia, c o nsti pati o n, diarr hea, 
v o miti n g, t hr o m b oc yt o p e nia, c o u g h, p yre xia, hea dac he, n e utr o pe nia, al o peci a, decrease d 
a p petite, a b d o mi nal pai n, bac k pai n, d ys p nea, pai n i n e xtre mities, h y p o kal e mia, a n xiet y, 
art hral gia, a n d dizzi ness .  A d verse reacti o ns h a v e n ot w orse n e d wit h c o nti n ue d t hera p y at t he 
sa me or re d u ce d d os e.  
Base d o n its mec ha nis m of acti o n, precli nical acti vit y a n d p har mac o ki netic ( P K) a n d t o xicit y 
pr ofile , talaz o pari b was selecte d f or cli nical e val u ati o n i n t u m ors wit h de m o nstrate d or p ote ntial 
defects i n D N A re pair pat h wa ys, s uc h as B R C A m utati o ns, P T E N d ysf u ncti o n or a b n or mal 
R A D 5 1 f oci f or mati o n .  Talaz o pari b  has b ee n s h o w n t o be hi g hl y selecti ve a n d p ote nt c yt ot o xic 
a ge nt i n h u ma n ca n cer cell li nes a n d i n a ni mal m o dels of t u m ors h ar b ori n g m utati o ns t hat 
c o m pr o mise D N A re p air pat h wa ys .  P har m ac o ki netic para meters de m o nstrate d a hi g h 
bi oa vaila bilit y wit h a distri b uti o n pr ofile i n dicati n g e xte nsi ve tiss ue distri b uti o n, a n d a d urati o n 
of e x p os ure s ufficie nt t o s u p p ort o nce dail y d osi n g .  C ha n ges i n he mat ol o g y para meters were 
earl y mar kers of t o xic ol o g y fi n di n gs .  A ne mia, t hr o m b oc yt o pe ni a, a n d n e utr o pe nia ha v e all b ee n 
I R B-3 1 9 1 3 versi o n 8  P a ge 1 7  of 4 6   2  Se pte m ber  2 0 2 0  o bser ve d, i ncl u di n g Gra de  3 -4 e ve nts .  T he e v e nts of fati g ue, n a usea, c o nsti pati o n, diarr hea, 
v o miti n g, c o u g h, p yre xia, hea dac h e, al o p ecia, d ecrease d a p petite, a b d o mi nal pai n, bac k pai n, 
d ys p nea, pai n i n t he e xtre mities, h y p o k ale mia, a n xiet y, art hral gia, a n d diz zi ness ha ve als o b ee n 
o bser ve d i n s u bjects recei vi n g talaz o pari b.  All patie nts are bei n g m o nit ore d f or 
m yel o -s u p pressi on i n t he o n g oi n g st u dies.  
T he  ta ble b el o w s u m marize s t he safet y d ata of  t alaz o pari b as ass esse d b y t he p hase  1  tri al i n 
patie n ts wit h a d va nce d s oli d t u m ors.2 5 
T a ble 1 .  Safet y dat a f or p hase  1  d ose es calati o n/e x pa nsi o n trial f or patie nts wit h s oli d ca ncers2 5 
 
I R B-3 1 9 1 3 versi o n 8  P a ge 1 8  of 4 6   2  Se pte m ber  2 0 2 0   
Fi g ure 2 .  B R C A 1/ B R C A 2  breast c a ncer R E CI S T waterfall pl ot i n p hase  1  trial of talaz o pari b2 5 
2. 6   R ati o n ale   
P ol y ( A D P -ri b ose) p ol y merase-1 ( P A R P 1) a n d P A R P 2 pla y i m p orta nt r ol es i n D N A re pair .7 T he 
cli nical de v el o p me nt of P A R P 1/ 2 i n hi bit ors a d va nce d w he n t he pri n ci ple of c h e mical s y nt hetic 
let halit y was esta blis he d i n B R C A 1/ 2-deficie nt cells .2 S y nt hetic let halit y st e ms fr o m t he i na bilit y 
of B R C A -defi cie nt cells t o u n der g o h o m ol o g o us rec o m bi nati o n -me diate d d o u ble -stra n d D N A 
brea k re pair, ma ki n g t he m s usce pti ble t o D N A da ma ge ca us e d b y a P A R P i n hi bit or .3, 5, 6 T w o 
p hase  2  pr o of -of -c o n ce pt st u dies d oc u me nte d o bjecti ve res p o nses t o si n gle a ge nt ola pari b, a n 
oral P A R P i n hi bit or, i n B R C A 1/ 2  m utati o n carri ers wit h a d v a n ce d o v aria n a n d breast ca n cer .1 3, 2 6  
Gi ve n t hat s p ora dic tri ple -ne gati ve breast ca n cers s h are ma n y p at h ol o gical a n d m olec ular 
feat ur es wit h breast ca ncers arisi n g i n t he setti n g of a here ditar y B R C A m utati o n, it was 
s u g geste d t hat t hese s p ora dic t u m ors mi g ht s hare si milar D N A re p air defects a n d s h o w si milar 
c he m ose nsiti vit y t o B R C A m utati o n -ass ociate d t u m ors .  T he acti vit y of si n gle -a ge nt ol a pari b, a 
b o na fi de P A R P i n hi bit or, was i n vesti gate d i n a s mall c o h ort of u nselecte d s p ora dic 
tri ple-ne gati ve breast ca ncer patie nts, h o we ver, n o o bjecti ve res p o nses were n ote d a n d f urt h er 
i n vesti gati o n was h alte d.1 3 T hese e x perie nces t h warte d t h e cli nical d e ve l o p me nt of P A R P 
i n hi bit ors i n s p ora dic tri ple-ne gati ve breast ca ncer .  T he i na bilit y t o select B R C A 1/ 2 wil d -t y p e 
t u m ors wit h u n derl yi n g D N A re p air defects f urt her c o m p o u n de d t he pr o bl e m. 
I R B-3 1 9 1 3 versi o n 8  P a ge 1 9  of 4 6   2  Se pte m ber  2 0 2 0  D ue t o t hes e earl y c halle n ges, t he r ole of P A R P i n hi biti o n i n t he tre at me nt of s p ora di c 
tri ple-ne gati ve breast ca n cer h as re mai n e d u n defi ne d .  T he c halle n ge at h a n d is t o a p pr o priat el y 
select patie nts lac ki n g a ger mli ne  B R C A 1/ 2 m utati o n f or t he ne xt ge nerati o n of cli nical trials .  
Patie nt C o h ort  A of o ur pr o p ose d st u d y wit h  t h e P A R P i n hi bit or talaz o pari b ai ms t o a d dress t his 
i m p orta nt q uesti o n b y selecti n g a s u b p o p ulati o n of s p ora dic, tri ple-ne gati ve breast ca ncer 
patie nts e nric he d f or h o m ol o g o us rec o m bi nati o n deficie nc y (H R D ) as assesse d b y a n o vel 
tiss ue-base d assa y d e vel o p e d b y M yri a d Ge netics .  T he  H R D  assa y has bee n de vel o pe d usi n g a n 
i n direct a p pr oac h t hat all o ws f or t he detecti o n of H R D  re gar dless of its eti ol o g y or mec ha nis m as 
assesse d b y l e vels of ge n o mic i nsta bilit y.1 6 O ur gr o u p has pre vi o usl y e val u ate d t he  H R D  assa y i n 
a ne o a dj u va nt p has e  2  tri al of ge mcita bi ne, car b o plati n a n d i ni pari b a n d s h o we d t hat a hi g h H R D  
sc ore si g nifi ca ntl y c orrel ate d wit h fa v ora ble pat h ol o gic res p o nse t o t his plati n u m -base d re gi me n 
i n earl y-sta ge tri ple-ne gati ve breast ca n cer p atie nts wit h a n d wit h o ut a ger mli ne  B R C A 1/ 2 
m utati o n .1 7, 1 9  
Gi ve n o ur fi n di n gs, we h y p ot hesize t hat t he  H R D  assa y ca n be use d t o select tri ple -ne gati ve 
breast ca n cer patie nts m ost li k el y t o deri ve be nefit fr o m a si n gle -a ge nt P A R P i n hi bit or treat me nt 
strate g y.  Talaz o pari b  is a n o vel oral P A R P 1/ 2 i n hi bit or s h o w n i n precli ni cal m o dels t o be m ore 
p ote nt t ha n ot her a ge nts i n its class a n d a rec o m m e n de d phas e  2  d ose has b ee n deter mi ne d .2 4, 2 5, 2 7 
As s uc h, it is a n i deal dr u g t o e val uat e i n a pr o of -of -c o nce pt st u d y of si n gle -a ge nt P A R P 
i n hi bit or t hera p y i n patie nts wit h a d va nce d tri ple-ne gati ve breast ca ncer, w h o lac k a ger mli ne  
B R C A 1 or B R C A 2 m utati o n,  b ut are  H R -defi cie nt b y t he  H R D  assa y.  
O ur sec o n d p atie nt c o h ort ( C o h ort  B) ai ms t o e v al uate t he efficac y a n d s afet y of tal az o pari b i n a n 
e mer gi n g s u b -gr o u p of breast ca ncer patie nts , or ot her n o n -breast metastatic s oli d t u m ors  wit h 
hi g h li keli h o o d of  H R  d eficie nc y st e m mi n g fr o m ger mli ne  or s o matic m utati o ns i n ge nes ot h er 
t ha n B R C A 1 a n d B R C A 2 i m plicate d i n t he d o u bl e-stra n de d D N A brea k re pair pat h w a y.  Bas e d 
o n t he li mite d c urre nt data, t he pre vale nce of s uc h here ditar y breast a n d o varia n ca ncer 
s y n dr o mes is esti mate d t o be as hi g h as 5 % of t he ge neral breast ca ncer p atie nt p o p ulati o n.1 4, 1 5 
Gi ve n t he i n crease d utilizati o n of c o m mercial m ulti ple x ger mli ne  ge ne pa nels  as well as t h e 
i ncreas e d a v aila bilit y of ne xt generati o n t u m or se q ue nci n g , we will li kel y  ca pt ure m ore of t hes e 
pati e nts i n c o m m u nit y a n d aca de mic  o nc ol o g y  practices  i n c o mi n g years; h o we ver, d ue t o t he 
c urre nt lac k of  cli nical trials assessi n g t he utilit y of P A R P i n hi bit ors i n t his heter o ge ne o us gr o u p 
of breast ca ncer patie nts, we d o n ot yet k n o w t he efficac y of s uc h a strate g y .  T h us, t his 
pr o of -of -c o nce pt st u d y will assess t he r ole of P A R P i n hi biti o n i n a d va nce d H E R 2 -ne gati v e 
breast ca ncer a n d ot h er n o n -breast s oli d t u m ors wit h pres u me d u n derl yi n g  H R -deficie nc y d ue t o 
a ger mli ne  or s o matic m utati o n i n t he  H R pat h wa y .  
I R B-3 1 9 1 3 versi o n 8  P a ge 2 0  of 4 6   2  Se pte m ber  2 0 2 0  2. 7   St u d y Desi g n  
T his is a si n gle -ar m, o pe n -la bel treat me nt pr ot oc ol desi g ne d t o e val uate t he efficac y a n d s afet y 
of talaz o pari b i n 2  patie nt c o h orts:  
  C o h ort  A : A d v a nce d s p ora dic, tri ple -n e gati ve breast ca n cer wit h h o m ol o g o us rec o m bi nati o n 
deficie nc y b ase d o n a hi g h  H R D  assa y sc ore  (H R D  sc ore ≥  4 2 ) 
  C o h ort  B : A d va n ce d H E R 2 -ne gati ve ( ie, E R a n d/ or P R p ositi ve or T N) breast ca n cer or 
ot her n o n -breast metastatic  ca ncer wit h  a d eleteri o us  or s us pecte d del eteri o us ger mli ne  or 
s o matic ge n e m utati o n i n t he h o m ol o g o us rec o m bi nati o n pat h wa y, e x cl u di n g B R C A 1 a n d 
B R C A 2 .  M utati o ns of i nterest are:  
o  P T E N ;  P A L B 2 ;  C H E K 2 ;  A T M ;  N B N ;  B A R D 1 ;  B RI P 1 ;  R A D 5 0 ;  R A D 5 1 C ;  
R A D 5 1 D ;  M R E 1 1 ;  A T R ;  Fa nc o ni a ne mia c o m ple me ntati o n gr o u p of ge nes ( F A N C A ;  
F A N C C ;  F A N C D 2 ;  F A N C E ;  F A N C F ;  F A N C G ;  F A N C L) ;  pl us ot her  H R -relate d 
ge n es a t t he discreti o n of t he pri mar y i n vesti gat ors . 
T his st u d y will pr ocee d wit h 2  p hases: scree ni n g a n d treat me nt .  D uri n g scree ni n g, all 
partici pa nts will be as ke d t o pr o vi de a metastatic t u m or  bi o ps y sa m ple t o assess t he H R D  sc ore 
base d o n t he  H R D  assa y.  T his res ult is re q uire d f or eli gi bilit y deter mi nati o n i n C o h ort  A .  If t he 
patie nt d oes n ot ha ve a n a de q uate  t u m or bi o ps y sa m ple fr o m a metastatic site, bi o ps y will be 
perf or me d d uri n g scree ni n g .  If t his is n ot feasi ble, we will use t he pri mar y  t u m or f or H R D  sc ore 
assess me nt .  At t his ti me, we will n ot be offeri n g s cree ni n g ger mli ne  testi n g t o assess t he 
prese nce of a delet eri o us B R C A 1 or B R C A 2 m utati o n n or t he ot her  H R pat h wa y ge n es of 
i nterest i n t his trial.  Patie nts w h o ha ve alr ea d y bee n i de ntifie d as h ar b ori n g a  deleteri o us  or 
s us pecte d d eleteri o us  ger mli ne  m utati o n i n t h e  H R pat h w a y o n m ulti ple x ger mli ne  p a nels 
(M y Ris k, A m br y, I n Vitae, B R O C A, or ot her C LI A a p pr o ve d assa y ) or t h ose patie nts w h o ha d an  
deleteri o us or s us p ecte d deleteri o us  H R pat h wa y s o matic m utati o n i de ntifie d t hr o u g h ne xt 
ge n erati o n s e q ue n ci n g  of t heir t u m or ( F o u n dati o n O ne or ot her C LI A a p pr o ve d assa y) will be 
eli gi ble f or tr eat me nt i n C o h ort  B .  All p atie nts will be as ke d t o pr o vi de a bl o o d s a m ple t o r u n 
t he m y Ris k here ditar y 2 5-ge ne pa n el f or researc h p ur p oses o nl y. 
Patie nts w h o are eli gi ble f or treat me nt i n C o h ort  A  i ncl u de t h os e w h o are B R C A 1 a n d B R C A 2 
wil d -t y pe, h a ve a d v a nce d  T N B C a n d a t u m or H R D  sc ore of ≥  4 2 .  
Patie nts w h o are eli gi ble f or treat me nt i n C o h ort  B  i ncl u de t h ose w h o are B R C A 1 a n d B R C A 2 
wil d -t y pe wit h H E R 2-n e gati ve a d va n ce d breast ca ncer or ot her n o n -breast s oli d t u m ors a n d 
eit her a d eleteri o us or s us pecte d del eteri o us ger mli ne  or  s o matic m utati o n i n H R pat h wa y -relate d 
ge n es be y o n d B R C A 1 a n d B R C A 2 .  T hese ge nes i ncl u de:  
P T E N ;  P A L B 2 ;  C H E K 2 ;  A T M ;  N B N ;  B A R D 1 ;  B RI P 1 ;  R A D 5 0 ;  R A D 5 1 C ;  R A D 5 1 D ;  
M R E 1 1 ;  A T R ;  Fa n c o ni a ne mia c o m ple m e ntati o n gr o u p of ge n es ( F A N C A ;  F A N C C ;  
F A N C D 2 ;  F A N C E ;  F A N C F ;  F A N C G ;  F A N C L) ;  pl us ot her  H R -relate d ge nes at t he 
discreti o n of t he pri mar y i n vesti gat ors .  
T he n o mi nal d urati o n of treat me nt is 3 6  c ycl es ( 2 8  da ys per c ycle), b ut C R, P R, or S D patie nts 
ma y c o nti n ue t hera p y u ntil e vi de nce of pr o gressi ve disease or u nacce pta ble t o xicit y occ urs .  
Pr ot oc ol t hera p y will be disc o nti n ue d  f or pr o gressi ve disease at a n y ti me.  Patie nts are free t o 
halt t hera p y at t heir re q u est.  Treat me nt ma y b e disc o nti n ue d if i nterc urre nt c o -m or bi dities occ ur, 
w hic h, i n t he o pi ni o n of t he treati n g p h ysicia n, w o ul d precl u de safe a d mi nistrati o n of st u d y dr u gs  
I R B-3 1 9 1 3 versi o n 8  P a ge 2 1  of 4 6   2  Se pte m ber  2 0 2 0  P ati e nts will be sc he d ule d f or f oll o w-u p  ge netic c o u nseli n g if acti o n a ble m ut ati o ns are 
f o u nd.   
3.   P A R TI CI P A N T S E L E C TI O N A N D E N R O L L M E N T P R O C E D U R E S  
3. 1  Eli gi bilit y Criteri a a n d P artici p a nt Eli gi bilit y C hec klist  
I n cl usi o n a n d E x cl usi o n Criteria are pr o vide d o n t he Eli gi bilit y  C hec klist f oll o wi n g, w hic h is t o 
be e xtracte d fr o m t his d o c u me nt f or use i n scree ni n g p ote ntial s u bjects.  F or eac h pr os pecti ve 
st u d y partici p a nt t hat is scree n e d, t his c hec klist will be pri nte d, c o m plete d i n its e ntiret y a n d t h e 
results rec or de d, a n d t he c hec klist will be file d i n t he res pecti ve s u bject  bi n der or file.  It is 
a ntici pate d t hat n ot all pr os pecti ve st u d y p artici pa nts t hat are scree n e d will be e nr olle d.   
P urs ua nt t o Sta nf or d Me dici ne S O P “ C o nfir mati o n of Partici pa nt Eli gi bilit y i n Cli nical Trials,” 
t he treati n g P h ysici a n (i n vesti gat or);  t he St u d y C o or di nat or;  a n d a n I n d e p e n de nt  Re vie wer will  
verif y t hat t he s u bject’s eli gi bilit y is acc urate;  c o m plete;  a n d le gi ble i n s o urce rec or ds.  
A  descri pti o n of t he eli gi bilit y v erificati o n pr o cess will be i ncl u de d i n t he E PI C or ot her 
Electr o nic Me dical Rec or d pr o gress n ote.  
  
I R B-3 1 9 1 3 versi o n 8  P a ge 2 6  of 4 6   2  Se pte m ber  2 0 2 0  3. 2   I nf or me d C o nse nt Pr ocess 
All pa tie nts m ust be pr o vi de d a c o nse nt f or m descri bi n g t he st u d y wit h s ufficie nt i nf or mati o n f or 
parti ci pa nts t o ma ke a n i nf or me d decisi o n re gar di n g t heir partici pati o n.  Partici pa nts m ust si g n 
t he I R B a p pr o ve d i nf or me d c o nse nt pri or t o partici pati o n i n a n y st u d y s pecific pr oce d ure.  T he 
partici pa nt m ust recei v e a c o p y of t he si g ne d a n d date d c o nse nt d o c u m e nt.  T he ori gi nal si g ne d 
c o p y of t he c o ns e nt d oc u me nt m ust be retai ne d i n t he me dical rec or d or res earc h file.  
3. 3   R a n d o miz ati o n Pr o ce d ures  
Patie nts will n ot be ra n d o mize d i n t his st u d y, as it is a n o pe n-la bel si n gle ar m trial c o nsisti n g of 
2  c o h orts, b o t h of w hic h will recei ve t he st u d y dr u g.  At least 1 0 H E R 2 -ne gati ve breast ca ncer 
patie nts will be e nr olle d i n C o h ort  B.  
3. 4   St u d y Ti meli ne  
Pri m ar y C o m pleti o n:   T he st u d y will reac h  pri mar y c o m pleti o n 3 6  m o nt hs fr o m t he ti me t he 
st u d y o pe ns t o accr ual.  T his is t he esti mate d ti me of accr ual of t he last patie nt ( n u m ber  2 0 ) i n 
eac h c o h ort . 
St u d y C o m pleti o n:  T he st u d y will reac h st u d y c o m pleti o n 3 6  m o nt hs fr o m t he ti me t he st u d y 
o pe ns t o accr ual.   
4.   T R E A T M E N T P L A N  
4. 1   Scree ni n g Pr oce d ures  
I nf or me d c o nse nt m ust be d oc u me nte d bef ore a n y trial-s pecific pr oce d ures or treat me nts are 
c o n d ucte d.  T his st u d y will ha ve a m olec ular pre -scree n c o ns e nt f or C o h ort  A  t o assess t he H R D  
sc ore usi n g F F P E t u m or tiss ue e val uate d b y t he M yria d H R D  assa y.  All patie nts w h o m eet 
eli gi bilit y criteria base d o n t he pre-s cree n c o nse nt will be pr o vi d e d  a writte n m ai n st u d y 
i nf or me d c o nse nt  d o c u me nt .  At t his ti me we will n ot be offeri n g s cree ni n g f or ger mli ne  or 
s o matic m utati o ns i n t he H R pat h wa ys ge nes of i nterest .  All patie nts e nr ol le d i n C o h ort  B of t his 
trial will ha ve a k n o w n deleteri o us or s us pecte d deleteri o us ger mli ne  or s o matic m utati o n i n a 
ge n e of i nterest pri or t o st u d y e nr oll me nt.  
T he f oll o wi n g s cree ni n g pr oce d ures will be perf or me d o n s u bjects c o nse nti n g f or m olec ular 
pre -scree ni n g f or C o h ort  A : 
  Deter mi nati o n of  H R D  s c ore bas e d o n f or m ali n fi x e d paraffi n e m be d d e d ( F F P E) 
metastatic t u m or site c ore bi o ps y .  If t he patie nt d oes n ot ha ve a n a de q uat e t u m or bi o ps y 
sa m ple fr o m a metast atic site, bi o ps y will be perf or me d d uri n g scree ni n g.  If t his is n ot 
feasi ble, we will use t he pri mar y t u m or f or H R D  s c ore ass ess me nt. 
T he f oll o wi n g scree ni n g pr oce d ures will be perf or me d o n c o nse nt e d a n d eli gi ble s u bjects after 
t he mai n st u d y c o ns e nt is si g ne d wit hi n 2 8 da ys  of i nitiati n g st u d y tre at me nt:  
  Me dical hist or y  
  C o m plete p h ysical e x a mi nati o n, i ncl u di n g hei g ht a n d wei g ht  
  Vital si g n assess me nt, i n cl u di n g bl o o d press ure a n d p ulse  
  Easter n C o o perati ve O nc ol o g y Gr o u p ( E C O G) Perf or ma nce Stat us assess me nt  
I R B-3 1 9 1 3 versi o n 8  P a ge 2 7  of 4 6   2  Se pte m ber  2 0 2 0    La b orat or y e val uati o n, i n cl u di n g C B C wit h d iffere ntial, c o m pre he nsi ve met a b olic pa nel, 
a n d uri ne pre g na nc y t est  
  Pat h ol o g y re vie w (i ncl u di n g re vi e w of E R/ P R/ H E R 2  f or breast ca ncers) of t u m or fr o m 
metastatic site or a bi o ps y of met astatic site, if n ot d o ne pre vi o usl y .  
  C T sca n wit h I V c o ntr ast of c he st, a b d o me n, a n d pel vis or P E T/ C T sca n wit h I V c o ntrast 
f or c o m plete disease e v al uati o n.  C o ntin ue t o use t he sa me e v al uati o n met h o d d uri n g t he 
st u d y as use d f or i nitial e val uati o n 
  M RI brai n  or C T h ea d, if pri or hist or y of brai n metastases 
  F or patie nts eli gi ble f or C o h ort  B, deter mi nati o n of  H R D  sc ore b ase d o n f or mali n fi x e d 
paraffi n e m be d de d ( F F P E) metastatic t u m or site c ore bi o ps y is r e q uire d, b ut is n ot nee de d 
f or eli gi bilit y a n d d oes n ot nee d t o be re p orte d pri or t o treat me nt i nitiati o n.  If t he patie nt 
d oes n ot ha ve a n a de q uat e t u m or bi o ps y sa m ple fr o m a metastatic site, bi o ps y will be 
perf or me d d uri n g scree ni n g .  If t his is n ot feasi ble, we will use t he pri mar y t u m or 
f or H R D  sc ore assess me nt. 
  Researc h ger mli ne  bl o o d c ollecti o n  
  Researc h M y Ris k ger mli ne  bl o o d c ollecti o n  
  Researc h pl as ma c ollecti o n  
  S u b missi o n of arc hi val t u m or tiss ue fr o m t he pri mar y breast t u m or  
4. 2   D osi n g a n d A d mi nistr ati o n Sc he d ule  
N O T E:      1  c ycle =  2 8  d a ys  
Talaz o pari b  will be a d mi nistere d at 1 milli gra m orall y dail y .  Talaz o pari b  s h o ul d be ta ke n at 
a p pr o xi matel y t he sa me ti me eac h d a y .  Talaz o pari b  will be ta ke n orall y a n d s wall o we d w h ole.  
All d osa ges prescri be d a n d dis pe nse d t o t he patie nt a n d all d ose c ha n ges d uri n g t h e st u d y m ust 
be rec or de d .  Me dicati o n la bels will c o m pl y wit h U S le gal re q uire m e nts a n d be pri nte d i n 
E n glis h .  T he y will s u p pl y n o i nf or m ati o n a b o ut t he patie nt.  
T he I P is talaz o pari b, a w hite t o off-w hite cr ystalli ne p o w der .  T he dr u g s u bsta n ce is a 
4 -met h yl be nze n es ulf o nat e (t os ylate) salt of talaz o pari b free base, the acti ve m oiet y .  T he dr u g 
pr o d uct c o nsists of t he dr u g s u bsta n ce f or m ulate d wit h a p har mace uticall y -s uita ble e x ci pie nt 
fille d i nt o h y dr o x y met h yl pr o p ylcell ul ose ca ps ul es.  Ca ps ules will be pr o vi de d t o t he site i n 3 
d ose stre n gt hs of 0. 1 0  m g , 0. 2 5 m g , a n d 1. 0  m g  ca ps ules .  T he d ose str e n gt hs are base d o n t he 
acti ve m oiet y ( t alaz o pari b free bas e).  T he ca ps ules are pr o vi de d i n d ose -s pecifi c c ol ors t o 
pr o vi de a vis ual met h o d of disti n g uis hi n g d ose stre n gt hs .  St u d y dr u g s h o ul d be st ore d at r o o m 
te m perat ur e ( 15  t o 3 0° C;  5 9  t o 8 6° F) .  T he ca ps ules are s u p plie d i n 3 0 -c o u nt i n d ucti o n -seale d 
hi g h -de nsit y p ol yet h yle ne ( H D P E) b ottles.  
T he i n vesti gat or s h o ul d pr o m ote c o m plia nce b y i nstr ucti n g t he p atie nt t o ta ke t he st u d y dr u g 
e x actl y as pres cri be d a n d b y st ati n g t ha t c o m plia nce is necessar y f or t he p atie nt’s safet y a n d t he 
vali dit y of t he st u d y .  T he patie nt s h o ul d be i nstr ucte d t o c o ntact t he i n vesti gat or if he/s he is 
u na ble f or a n y reas o n t o ta ke t he st u d y dr u g as prescri be d.  
I R B-3 1 9 1 3 versi o n 8  P a ge 2 8  of 4 6   2  Se pte m ber  2 0 2 0  C a ps ules  
T he ca ps ules  s h o ul d be s wall o we d w h ole wit h a glass of water a n d s h o ul d n ot be c he we d or 
cr us he d.  If v o miti n g occ urs, n o atte m pt s h o ul d be ma de t o re place t he v o mite d d ose.  Patie nts 
s h o ul d be i nstr ucte d t hat if t he y miss a d ose o n o ne da y, t he y m ust n ot ta ke a n y e xtra d ose t he 
ne xt d a y, b ut i nstea d t o i m me diatel y c o ntact t he st u d y ce nter as s o o n as p ossi ble t o as k f or 
a d vice.  
Patie nts ma y c o nti n ue c o nc o mita nt me dicati o ns  f or ot her c o n diti o ns a n d a n y a d diti o nal 
a p pr o priate s u p p orti ve care me dicati o ns or treat me nts.   
4. 3   Pre -T re at me nt E v al u ati o ns  
Patie nts will be e val uate d i n cli nic o n Da y  1 of eac h c ycle .  F or t he first c ycle, we will als o 
re q uire a mi d-c ycle p h ysi cia n's visit .  F urt her m ore,  wee kl y C B C wit h diff will be re q uire d f or t he 
first c ycle ( q 7 d a ys +/- 3  da ys) a n d bi wee kl y  ( q 14 da ys +/ - 3  da ys)  C B C wit h diff will be 
re q uire d f or t he sec o n d c ycl e.  S u bse q ue nt t o t his, we will o nl y re q uire a C B C wit h diff per c ycle 
( q 4 wee ks +/- 3  da ys) .  La b orat or y tests ca n be p er f or me d e xter nall y a n d fa x e d t o t he PI/r esearc h 
tea m.  T he f oll o wi n g ass ess me nts will be perf or m e d at eac h p h ysicia n's visit : 
  P h ysical e xa mi nati o n, i ncl u di n g wei g ht  
  Vital si g ns, i ncl u di n g bl o o d press ure, p ulse, a n d te m perat ure  
  E C O G Perf or ma nce Stat us assess me nt  
  Cli nical la b orat or y tests:  C B C wit h differe ntial a n d c o m pre he nsi ve m eta b olic pa nel  
  Uri ne pre g n a nc y test  (fe male s u bjects of c hil d beari n g p ote ntial) 
  Assess me nt of c o nc o mita nt me dicati o ns  
  Assess me nt of a d verse e ve nts a n d d ose m o dificati o ns as necessar y.  A d verse e ve nts 
s h o ul d be m o nit ore d c o nti n u o usl y 
  T u m or e val uat i o n wit h i ma gi n g e v er y 2 c ycles ( 8 wee ks +/- 1 wee k)  
4. 4   E n d of Tre at me nt Pr o ce d ures  
If patie nts are n o l o n ger recei vi n g treat me nt, t he assess me nts s h o ul d be c o m plete d wit hi n 
3 0  da ys of t he last d ose of talaz o pari b.   
  P h ysical e xa mi nati o n, i ncl u di n g wei g ht  
  Vital si g ns, i ncl u di n g bl o o d press ure, p ulse, a n d te m perat ure  
  E C O G Perf or ma nce Stat us assess me nt  
  Cli nical la b orat or y tests: C B C wit h differe ntial, c o m pre he nsi ve meta b olic pa nel  
  Uri ne pre g n a nc y test  (fe male s u bjects of c hil d beari n g p ote ntial) 
  Assess me nt of  a d verse e ve nts  
  St u d y dr u g c o m plia nce ( pill diar y)  
I R B-3 1 9 1 3 versi o n 8  P a ge 2 9  of 4 6   2  Se pte m ber  2 0 2 0  4. 5   Ge ner al C o nc o mit a nt Me dic ati o n a n d S u p p orti ve C are G ui deli nes  
C o nc o mita nt treat me nt is per mitte d if t he me dicati o n is n ot e x pecte d t o i nterfere wit h t he 
e val uati o n of safet y or efficac y of t he st u d y dr u g .  D uri n g t he st u d y, if t he use of a n y 
c o nc o mita nt treat me nt bec o mes necessar y ( e g, f or treat me nt of a n a d verse e ve nt), t he treat me nt 
m ust be d oc u me nte d, i ncl u di n g t he reas o n f or tr eat me nt, ge neric na me of t he dr u g, d osa ge, r o ute, 
a n d start a n d st o p da tes of a d mi nistrati o n. 
A ll s u p p orti ve meas ures c o nsiste nt wit h o pti mal patie nt care will be gi ve n t hr o u g h o ut t he st u d y.  
T he cli nical t olera nce of t he patie nt, t he o verall t u m or res p o nse, a n d t he me dical j u d g me nt of t he 
i n vesti gat or will deter mi ne if it is i n t he patie nt’s best i nterest t o c o nti n ue or disc o nti n ue 
treat me nt.  If treat me nt is disc o nti n ue d d ue t o a n y t o xicit y, t he p atie nt m ust be f oll o we d t o 
m o nit or d urati o n of t o xicit y, res p o nse a n d ti me t o pr o gressi o n or s ur vi val a n d i nitiati o n of a n y 
ne w s y st e mic t hera p y.  
4. 6   D ur ati o n of T her a p y a n d F oll o w -U p  
T he n o mi nal d urati o n of treat me nt is 3 6  c ycl es ( 2 8  da ys per c ycle), b ut C R, P R, or S D patie nts 
will c o nti n ue t hera p y u ntil e vi de nce of pr o gressi ve disease or  u n acce pta ble t o xicit y occ urs.  
Pr ot oc ol t he ra p y will be disc o nti n ue d f or pr o gressi ve disease at a n y ti me.  Patie nts are free t o 
halt t hera p y at t heir re q u est.  Treat me nt ma y b e disc o nti n ue d if i nterc urre nt c o -m or bi dities occ ur, 
w hic h, i n t he o pi ni o n of t he treati n g p h ysicia n, w o ul d precl u de safe a d mi nistrati o n of st u d y 
dr u gs.  
4. 7   Criteri a f or Re m o v al f r o m St u d y  
Patie nts M U S T be disc o nti n ue d fr o m st u d y t hera p y A N D be wit h dr a w n fr o m t he st u d y f or t he 
f oll o wi n g reas o ns:  
  Wit h dra wal of t he patie nt’s c o nse nt ( patie nt’s d ecisi o n t o wit h dra w f or a n y reas o n)  
  A n y cli nical a d verse e v e nt, la b orat or y a b n or m alit y or i nterc urre nt ill ness w hic h, i n 
t he o pi ni o n of t he i n vesti gat or, i n dicates t hat c o nti n ue d partici pati o n i n t he st u d y is 
n ot i n t he best i nterest of t he s u bject  
  I n a bilit y t o c o m pl y wit h pr ot oc ol  
  Dis creti o n of t he i n vesti gat or  
  Disease pr o gressi o n ( pati e nt c o nti n ue t o be f oll o we d f or s ur vi val) 
  Deat h  
If a s u bject is wit h dra w n bef ore c o m pleti n g t h e st u d y, t he reas o n f or wit h dr a wal m ust be e ntere d 
o n t he a p pr o priat e cas e re p ort f or m.   
4. 8   Alter n ati ves  
Alt er nati ves t o partici pati o n i n t his cli nical trial i ncl u de use of c he m ot hera pe utic a ge nts f or t h e 
treat me nt of metastatic tri ple-ne gati ve breast c a ncer .  Alter n ati ves f or metastatic E R a n d/ or 
P R -p ositi ve, H E R 2 -ne gati ve breast c a ncer i ncl u de a nti-estr o ge n t hera p y a n d c he m ot hera p e utic 
a ge nts.  
I R B-3 1 9 1 3 versi o n 8  P a ge 3 0  of 4 6   2  Se pte m ber  2 0 2 0  4. 9   C o m pe ns ati o n  
Patie nts ma y be eli gi ble f or tra vel a n d m eal rei m b urse me nt if t he y li ve m ore t ha n 5 0 miles fr o m 
st u d y site.   
5.   I N V E S TI G A TI O N A L A G E N T/ D E VI C E/ P R O C E D U R E I N F O R M A TI O N  
5. 1   I n vesti g ati o n al A ge nt   
Please n ote t hat more c o m plete i nf or mati o n ca n b e o btai ne d fr o m t he I n vesti gat or’s Br oc h ure 
(I B). 
Talaz o pari b  is a n o vel p ol y( A D P-ri b ose) p ol y merase ( P A R P) i n hi bit or.  T he acti ve i n gre die nt is 
talaz o pari b; t he c he mical na me is 3H -P yri d o[ 4, 3, 2 -de] p ht halazi n -3 -o ne, 
5 -flu or o -8 -( 4-fl u or o p he n yl)-2, 7, 8, 9 -tetra h y dr o-9 -( 1-met h yl -1 H -1, 2, 4 -triaz ol-5 -yl) -, ( 8S , 9R )-, 
4 -met h yl be nze nes ulf o nate ( 1: 1).  
C he mical str uct ure of talaz o pari b: 
 
M olec ular F or m ula ( tal az o pari b): C 2 6 H 2 2 F 2 N 6 O 4 S 
M olec ular Wei g ht ( talaz o pari b): 5 5 2. 5 6 2 4 
Talaz o par i b is ma n ufact ure d b y c he mical s y nt hesis i n acc or da nce wit h c urre nt G o o d 
Ma n ufact uri n g Practices (c G M P) .  T he dr u g pr o d uct is a ca ps ule f or m ulati o n c o m prise d of a 
ble n d of talaz o pari b dr u g s u bsta nce a n d silicifie d micr ocr ystalli ne cell ul ose fille d i nt o a 
h y pr o mell ose ca ps ule .  T he ca ps ule is prese nte d i n f o ur stre n gt hs –  2 5 -μ g ;  5 0 -μ g ;  2 5 0 -μ g ;  or 
1 -m g talaz o pari b free bas e e q ui vale nt –  t hat are disti n g uis he d eit her b y ca ps ule c ol or or siz e. 
Talaz o pari b is c o nsi dere d a c yt ot o xic a ge nt; preca uti o ns re gar di n g a p pr o priate sec ure st ora ge 
a n d ha n dli n g m ust b e us e d b y h ealt hcare pr ofessi o nals, i ncl u di n g pers o nal pr otecti ve cl ot hi n g, 
dis p osa ble gl o ves a n d e q ui p me nt .  S u bjects s h o ul d be a d vise d t hat oral a ntica n cer a ge nts are 
t o xic s u bsta nces a n d t h at ( ot her t h a n the s u bject) care gi vers s h o ul d al wa ys use gl o v es w he n 
ha n dli n g t he ca ps ules.  
5. 2   P h ar m a c o d y n a mi c Pr o perties   
Pri mar y P D st u dies ass esse d talaz o pari b a n d relate d c o m p o u n ds f or i n vitr o a n d i n viv o 
p har mac ol o gical acti vities .  Assess me nt of tal az o pari b effect s i n t u m or cell i nc u bati o ns re veale d 
selecti ve a n d p ote nt c yt ot o xicit y i n h u ma n ca ncer cell li nes har b ori n g m utati o ns t hat c o m pr o mise 
D N A re pair p at h wa ys .  Ge ne m utati o ns t hat c o nfer sel ecti ve t u m or cell c yt ot o xicit y i ncl u de d 
I R B-3 1 9 1 3 versi o n 8  P a ge 3 1  of 4 6   2  Se pte m ber  2 0 2 0  B R C A 1 ( M X -1 ma m mar y t u m or cell s);  B R C A 2 ( Ca pa n -1 pa n creatic t u m or cells) ;  P T E N 
( M D A-M B -4 6 8 ma m mar y ;  L N Ca p a n d P C -3 pr ostate t u m or cells) ;  a n d M L H -1 m utati o ns 
( H C T-1 1 6 c ol or ectal t u m or cells) .  T he I C 5 0 val ues of tal az o pari b i n t hes e t u m or cell li nes were 
i n t he si n gl e di git na n o m olar or s u b -na n o m olar ra n ge .  I n c o ntr ast, t he I C 5 0 of talaz o pari b a gai nst 
n or mal h u ma n pri mar y cell M R C -5 a n d se veral t u m or cell li nes t hat d o n ot ha ve re p orte d D N A 
re pair-relat e d m utati o ns are si g nifica ntl y greater ( 2 5 0 n M  t o >  1 0 0 0  n M ). 
5. 3   P h ar m a c o ki neti c Pr o perties   
T he p har mac o ki n etic ( P K) res ults f or t he d ose escalati o n p hase of P R P -0 0 1 ha ve bee n assess e d 
wit h preli mi nar y c o nce ntrati o n data fr o m 2 5  μ g / da y t hr o u g h 1 1 0 0 μ g / d a y.  I n c ycl e 1, sa m ples 
were c ollecte d f or a wee k after t he first si n gle d ose ( Da y  1) of a c o h ort, pre -d ose sa m ples were 
c ollecte d d uri n g dail y d osi n g (tr o u g hs), a n d sa m ples were c ollect e d f or a wee k after t he last d ose 
i n c ycle 1 (Da y  3 5) .  F oll o wi n g a si n gle d ose ( Da y  1), mea n plas ma C ma x a n d A U C 0 -2 4 hr ra n ge d 
fr o m 6 0. 0 t o 1 3, 2 0 0  p g /m L  a n d fr o m 9 5 3  t o 9 2, 1 0 0  p g -hr/ m L , res pecti vel y, o ver t he 
2 5  t o 1 1 0 0  μ g  d ose ra n ge .  F oll o wi n g m ulti ple dail y d osi n g ( Da y  3 5), mea n plas ma C ma x a n d 
A U C 0 -2 4 hr ra n ge d fr o m 3 0 0 t o 2 3, 4 0 0  p g/ m L  a n d fr o m 3 9 6 0  t o 2 0 3, 0 0 0  p g -hr/ m L , res pecti vel y, 
o ver t he 2 5 t o 1 1 0 0  μ g / da y d os e ra n ge.  At t he defi ne d ma xi m u m t olerate d d ose ( M T D) of 
1 0 0 0  μ g / da y, mea n ( S D) C ma x a n d A U C 0 -2 4 hr were 2 1, 0 0 0 ( 7, 9 9 0)  p g /m L  a n d 2 0 3, 0 0 0 
( 5 4, 8 0 0) p g -hr/ m L , res p ecti vel y, o n Da y  3 5 .  T he plas ma pr ofiles i n dicate e nter o he p atic c ycli n g 
of talaz o pari b beca us e of t he a d diti o nal c o n ce ntr ati o n pea ks be y o n d T ma x.  Eli mi nati o n a p pears t o 
be bi -e x p o ne ntial .  Mea n  talaz o pari b t 1/ 2 ra n ge d fr o m 5 3. 5 t o 2 3 4  h o urs  a n d fr o m 
4 0. 4  t o 1 1 5  h o urs  o n Da y  1 a n d Da y  3 5, res p ecti vel y .  At t he u p per e n d of t he d ose ra n ge 
e val uate d ( 9 0 0  t o 1 1 0 0  μ g ), t 1/ 2 ra n ge d fr o m 5 3. 5 t o 6 6. 1  h o urs  a n d fr o m 4 0. 4  t o 5 1. 8  h o urs  o n 
Da y  1 a n d Da y  3 5, res pecti vel y .  Stea d y state was a p pare nt i n m ost patie nts b y t w o wee ks wit h 
dail y d osi n g .  Acc u m ulati o n base d o n A U C 0 -2 4 hr was o bser ve d f or all pati e nts c o m pari n g Da y  3 5 
wit h Da y  1 a n d mea n val ues ra n ge d fr o m 2. 4 2  t o 9. 9 2 a n d fr o m 2. 4 2  t o 3. 6 9 acr oss t he 
2 5  t o 1 1 0 0  μ g  d ose ra n ge a n d t h e 9 0 0  t o 1 1 0 0  μ g  d os e ra n ge, res pecti vel y .  F oll o wi n g si n gle 
d oses, talaz o pari b C ma x a n d A U C 0 -2 4 hr were li near bet wee n 4 0 0 a n d 1 1 0 0  μ g .  F oll o wi n g 
m ulti ple d oses, talaz o pari b C ma x a n d A U C 0 -2 4 hr were li near bet w ee n 2 5 a n d 1 1 0 0  μ g / da y.  
A f o o d effect st u d y ( 6 7 3 -1 0 3) i n 1 8 healt h y v ol u nteers has bee n c o m plete d .  T his st u d y s h o w e d 
t hat w hile a hi g h-fat, hi g h cal orie m eal dela ye d t h e a bs or pti o n of orall y a d mi nistere d talaz o pari b, 
it di d n ot affect t he o verall e xte nt of t he a bs or pti o n.  Base d o n t hese fi n di n gs, talaz o pari b ca n be 
a d mi nistere d wit h o ut re gar d t o f o o d.  
5. 4   S u p plier  
T he i n vesti gati o nal a ge nt, talaz o pari b, will be pr o vi de d b y Pfizer P har mace utical, I nc.   
5. 5   D os a ge F or m  
Talaz o pari b  will be s u p plie d as ca ps ules f or oral a d mi nistrati o n.  
5. 6   A ge nt Or deri n g  a n d P a c k a gi n g  
Re q uests f or s hi p me nts of t he i n vesti gati o nal a ge nt will be c o or di nate d b y t he st u d y c o or di nat or 
directl y wit h  Pfizer  P har mace utical, I nc.  B ottles will c o ntai n a s uffici e nt n u m ber of ca ps ules f or 
o ne c ycle of d osi n g.   
I R B-3 1 9 1 3 versi o n 8  P a ge 3 2  of 4 6   2  Se pte m ber  2 0 2 0  5. 7   St or a ge a n d s helf life  
Sta bilit y d ata o btai n e d f or b ot h pr ot ot y pe a n d cli nical dr u g pr o d uct bat c hes c urre n tl y s u p p ort 
retest dati n g of 3 6 m o nt hs f or dr u g pr o d uct .  B ot h dr u g pr o d uct a n d dr u g s u bsta nce e x hi bit 
e x celle nt sta bilit y tr e n ds .  T he dr u g pr o d uct is st ore d at r o o m te m perat ure ( 1 5  t o 3 0  de g  C; 
5 9  t o 8 6  de g  F) a n d s h o ul d be pr otecte d fr o m li g ht.  
5. 8   N at ure a n d C o nte nts of C o nt ai ner  
T he ca ps ules a re pac k a ge d i n perf orate d u nit-d ose blister car ds c o m p ose d of c ol d f or m 
al u mi n u m f oil a n d p us h t hr o u g h al u mi n u m li d di n g .  T he 4  ca ps ule stre n gt hs are pac k a ge d i nt o 
t he sa me blister car d desi g n.  A d diti o nall y, 2 5 0 -μ g ca ps ules ( o pa q ue w hite, siz e 4) are pac k a ge d 
i n 3 0-c o u nt H D P E b ottles wit h a n i n d ucti o n seal a n d c hil d -resista nt ca p.  
5. 9   S peci al Prec a uti o ns f or Dis p os al a n d Ot her H a n dli n g  
A n y u n us e d pr o d uct or waste material is t o be dis p ose d of i n acc or da n ce wit h l ocal re q uir e me nts.   
6.   D O S E M O DI FI C A TI O N S  
Dail y d osi n g of talaz o pari b ca n be i nterr u pte d f or rec o ver y fr o m t o xicit y f or u p t o 2 8  da ys .  
T hereafter,  tr eat me nt at t he sa me or a re d u ce d d ose ca n be c o nsi dere d bas e d o n t he discreti o n of 
t he pri mar y i n vesti gat or if t he s u bject has n ot de vel o pe d pr o gressi ve disease.  D ose 
m o dificati o ns  s h o ul d be ma de base d o n o bs er ve d t o xicit y as f oll o ws: 
  Gra de  1 or 2 t o xicit y:  N o re q uire me nt f or d ose i nterr u pti o n or d ose re d ucti o n .  If t he 
t o xicit y persists at Gra de  2, a d ose re d u cti o n t o t he ne xt l o wer d ose le vel (e g,  fr o m 
1. 0  m g / da y t o 0. 7 5  m g/ da y) ma y be i m ple me nte d at t he discreti o n of t he I n vesti gat or  
  Gra de  3 t o xicit y:  Dail y d osi n g s h o ul d be st o p pe d .  Talaz o pari b  d osi n g ma y res u me at  t he 
ne xt l o wer d ose le vel (e g,  fr o m 1. 0 m g / da y t o 0. 7 5  m g / da y; 0. 7 5  m g / da y t o 0. 5  m g / da y;  
0. 2 5  m g / da y t o 0. 1 0  m g / da y) w he n t o xicit y res ol ves t o Gra de  1 or ret ur ns t o baseli ne  
  Gra de  4 t o xicit y:  Dail y d osi n g s h o ul d be st o p pe d .  Talaz o pari b  ma y res u m e at a l o wer 
d ose le vel ( 1  t o 2 d ose le vel decrease) wit h t he a p pr o val of t he PI  w he n t o xicit y res ol v es 
t o Gra de  1 or ret ur ns t o b aseli ne  
T a ble 3 .  D ose m o dificati o ns f or t o xicities  
  D ose Le vel  
I nitial d ose le vel  1. 0  m g / da y 
First d ose le vel r e d ucti o n  0. 7 5  m g / da y 
Sec o n d d ose le vel r e d ucti o n  0. 5  m g / da y 
T hir d d ose le vel r e d ucti o n  0. 2 5  m g / da y 
F o urt h d ose le vel re d ucti o n  0. 1 0  m g / da y 
Talaz o pari b  will be per m a ne ntl y disc o nti n ue d f or i n di vi d ual s u bjects as a res ult of a n y  
u nres ol ve d Gra de  3 or Gra de  4 t o xicit y or base d o n a decisi o n b y t he s u bject or I n vesti gat or t hat 
c o nti n ue d talaz o pari b treat me nt is n ot i n t he s u bject’s best i nterest. 
I R B-3 1 9 1 3 versi o n 8  P a ge 3 3  of 4 6   2  Se pte m ber  2 0 2 0  7 .  A D V E R S E E V E N T S A N D R E P O R TI N G P R O C E D U R E S  
7. 1   P ote nti al A d verse E ve nts  
Acc or di n g t o t he I C H defi niti o n, a n a d verse e ve nt ( A E) is a n y u nt o w ar d m e dical occ urre nce i n a 
patie nt or cli nical i n vesti gati o n s u bjec t a d mi nistere d a p har mace utical pr o d uct, a n d t hat d oes n ot 
necessaril y h a ve a ca us al relati o ns hi p wit h t his treat me nt.  A n A E ca n t heref ore be a n y 
u nfa v ora bl e a n d u ni nte n de d si g n (i ncl u di n g a n a b n or mal la b orat or y fi n di n g), s y m pt o m, or 
disease te m p orall y as s ociate d wit h t he use of a me dici nal (i n vesti gati o nal) pr o d uct, w het her or 
n ot c o nsi dere d relate d t o t he i n vesti gati o nal pr o d u ct.  
T his defi niti o n i ncl u des i nterc urre nt ill nesses or i nj uries t hat re pres e nt a n e x acer bati o n (i ncreas e 
i n fre q ue nc y, s e verit y, or s pecificit y) of pre-e xisti n g c o n diti o ns.  W he ne ver p ossi ble, it is 
prefera ble t o rec or d a dia g n osis as t he A E t er m rat her t ha n a s eries of ter ms relati n g t o a 
dia g n osis .  A d verse e ve nt i nf or mati o n will be c ollecte d i n a n o n g oi n g fas hi o n t hr o u g h p atie nt 
re p orti n g A Es t o t heir p h ysicia n or healt h care pr o vi der.  Seri o us n ess a n d relate d n ess will be 
assesse d b y t he treati n g p h ysicia n, wit h a p pr o priat e re p orti n g.  
A desi g nate d pri mar y c o ntact pers o n base d at t he treat me nt ce nter will be res p o nsi ble f or t he 
c ollecti o n a n d re p orti n g of A Es f or patie nts partici pati n g i n t he pr o gra m.   
A d verse e ve nts t hat be gi n or w orse n after i nf or m e d c o ns e nt s h o ul d be rec or de d i n t h e A d verse 
E ve nts C R F .  C o n diti o ns t hat were alr ea d y pres e nt at t he ti me of i nf or me d c o nse nt s h o ul d b e 
rec or de d i n t he Me dical Hist or y pa ge of t he patie nt’s C R F.  A d verse e ve nt m o nit ori n g s h o ul d be 
c o nti n ue d f or at least 3 0  da ys ( or 5  half -li ves, w hic he ver is l o n ger) f oll o wi n g t he last d ose of 
st u d y tr eat me nt.  A d verse e v e nts (i ncl u di n g la b a b n or malities t hat c o nstit ute A Es) s h o ul d be 
descri be d usi n g a dia g n osis w he ne ver p ossi ble, rat her t ha n i n di vi d ual u n derl yi n g si g ns a n d 
s y m pt o ms.  W he n a cl ear dia g n osis ca n n ot be i de ntifie d, eac h si g n or s y m pt o m s h o ul d be 
re p orte d as a se p arate A d verse E ve nt. 
T he occ ur re nce of a d v erse e v e nts s h o ul d be s o u g ht b y n o n-dir ecti ve q u esti o ni n g of t he patie nt at 
eac h visit d uri n g t he st u d y.  A d verse e ve nts als o ma y be det ecte d w he n t he y are v ol u nteere d b y 
t he patie nt d uri n g or bet wee n visits or t hr o u g h p h ysical e x a mi nati o n, la borat or y test, or ot her 
assess me nts .  As far as p ossi ble, eac h a d v erse e ve nt s h o ul d be e val uate d t o deter mi ne:  
  T he se verit y gra de ( C T C A E Gra d e  1  t o 4)  
  Its d ur ati o n (start a n d e n d dates or if c o nti n ui n g at t he Safet y F oll o w-u p Visit)  
  Its r elati o ns hi p t o t he st u d y treat me nt ( Reas o n a ble p ossi bilit y t hat A E is rel ate d: N o, Yes)  
  Acti o n ta ke n wit h res p ect t o st u d y or i n vesti gati o nal treat me nt ( n o ne, d ose a dj uste d, 
te m p oraril y i nterr u pte d, per ma ne ntl y disc o nti n ue d, h os pitalize d, u n k n o w n, n ot 
a p plica ble)  
  W het her me dicati o n or t hera p y was gi ve n ( n o c o nc o mita nt me dicati o n/ n o n -dr u g t hera p y, 
c o nc o mita nt me dicati o n/ n o n -dr u g t hera p y)  
  O utc o me ( n ot  rec o vere d/ n ot res ol ve d;  rec o v ere d/res ol ve d;  rec o veri n g/r es ol vi n g;  
rec o vere d/r es ol ve d wit h se q ualae;  fatal;  u n k n o w n)  
  W het he r it is seri o us, w here a s eri o us a d v erse e ve nt ( S A E) is defi ne d as i n Secti o n  7. 1. 2  
I R B-3 1 9 1 3 versi o n 8  P a ge 3 4  of 4 6   2  Se pte m ber  2 0 2 0  All a d verse e ve nts s h o ul d be treate d a p pr o pri atel y .  S uc h treat me nt ma y i ncl u de c ha n ges i n st u d y 
dr u g tr eat me nt i ncl u di n g p ossi ble i nterr u pti o n or disc o nti n uati o n, starti n g  or st o p pi n g 
c o nc o mita nt treat me nts, c ha n ges i n t h e fre q ue n c y or nat ur e of assess me nts, h os pitalizati o n, or 
a n y ot her me dicall y re q uire d i nter ve nti o n .  O nce a n a d v erse e ve nt is d etecte d, it s h o ul d be 
f oll o we d u ntil its res ol uti o n, a n d assess me nt s h o ul d be ma de at eac h visit ( or m ore fre q ue ntl y, if 
necessar y) of a n y c ha n ges i n se v erit y, t h e s us pecte d rel ati o ns hi p t o t he st u d y dr u g, t he 
i nter ve nti o ns re q uire d t o treat it, a n d t he o utc o me. 
I nf or mati o n a b o ut c o m m o n si de effects alrea d y k n o w n a b o ut t he i n vesti gati o nal dr u g ca n b e 
f o u n d i n t he I n v esti gat ors’ Br oc h ure.  T his i nf or mati o n s h o ul d be i n cl u de d i n t he p atie nt 
i nf or me d c o nse nt a n d s h o ul d be disc usse d wit h t he patie nt d uri n g t he st u d y as nee de d.  A d verse 
e ve nt m o nit ori n g s h o u l d be c o nti n ue d f or at least 3 0 da ys f oll o wi n g t he last d ose of st u d y 
treat me nt. 
Gi ve n ot her dr u gs i n t his class ha ve bee n ass oci ate d wit h he mat ol o gic mali g na n cies, s uc h as 
m yel o d ys plastic s y n dr o me ( M D S) a n d ac ute le u ke mias, a n y pr ol o n ge d c yt o p e nias, defi ne d as 
greater t ha n 6  wee ks, wil l be t h or o u g hl y e v al uate d i ncl u di n g referral t o he mat ol o g y cli nic, w here 
r o uti ne pr oce d ures i ncl u di n g b o ne marr o w bi o ps y, if dee me d a p pr o priate, will be c o n d ucte d.  
7. 1. 1  L a b or at or y test a b n or m alities  
La b orat or y a b n or malit ies t hat c o nstit ute a n A d verse Eve nt i n t heir o w n ri g ht (are c o nsi dere d 
cli nicall y si g nifica nt, i n d uce cli nical si g ns or s y m pt o ms, re q uire c o nc o mit a nt t hera p y or re q uire 
c ha n ges i n st u d y treat me nt), s h o ul d be rec or de d o n t he A d verse E ve nts C R F .  W he ne ver 
p ossi ble, a dia g n osis, rat her t ha n a s y m pt o m s h o ul d be pr o vi de d ( e g, a ne mia i nstea d of l o w 
he m o gl o bi n) .  La b orat or y a b n or malities t hat meet t he criteria f or A d verse E ve nts s h o ul d b e 
f oll o we d u ntil t he y h a ve ret ur n e d t o n or m al or a n a de q u ate e x pla nati o n of t he a b n or malit y is 
f o u n d.  W he n a n a b n or mal la b orat or y or test res ult c orres p o n ds t o a si g n/s y m pt o m of a n alrea d y 
re p orte d a d v erse e ve nt, it is n ot necessar y t o se p aratel y rec or d t he la b/test res ult as a n a d diti o nal 
e ve nt.  
La b orat or y a b n or malities, t hat d o n ot meet t he defi niti o n of a n a d v e rse e ve nt, s h o ul d n ot be 
re p orte d as a d verse e ve nts.  A Gra de  3 or 4 e ve nt (se vere) as per C T C A E d oes n ot a ut o maticall y 
i n dicate a S A E u nless it meets t he defi niti o n of seri o us as defi ne d bel o w a n d/ or as p er 
i n vesti gat or’s discreti o n.  A d ose h ol d or me dic ati o n f or t he la b a b n or malit y ma y be re q uire d b y 
t he pr ot oc ol a n d is still, b y defi niti o n, a n a d verse e ve nt. 
7. 1. 2   Seri o us A d verse E ve nts  ( S A E)  
A seri o us a d verse e v e nt is a n u n desira ble si g n, s y m pt o m or me dical c o n diti o n w hic h:  
  is fatal or life-t hr eate ni n g 
  res ults i n persiste nt or si g nifica nt disa bilit y/i n ca pacit y 
  c o nstit utes a c o n ge nital a n o mal y/ birt h defect  
  re q uires i n patie nt h os pitalizati o n or pr ol o n gati o n of e xisti n g h os pitalizati o n, u nless 
h os pitalizati o n is f or:  
o  electi ve or pre-pla n ne d tr eat me nt f o r a pre-e xisti n g c o n diti o n t hat is u nrelat e d t o 
t he i n dicati o n u n der st u d y a n d h as n ot w orse n e d si nce t he start of st u d y dr u g 
I R B-3 1 9 1 3 versi o n 8  P a ge 3 5  of 4 6   2  Se pte m ber  2 0 2 0  o  treat me nt o n a n e m er ge n c y o ut p atie nt basis f or a n e ve nt n ot f ulfilli n g a n y of t he 
defi niti o ns of a S A E gi v e n a b o ve a n d n ot r es ulti n g i n h os pital a d missi o n  
o  s ocial reas o ns a n d res pite care i n t he a bse n ce of a n y det eri orati o n i n t he pati e nt’s 
ge n eral c o n diti o n  
o  is me dicall y si g nifica nt, i e, defi ne d as a n e v e nt t hat je o par dizes t he patie nt or ma y 
re q uire me di cal or s ur gical i nter ve nti o n to pre ve nt o ne of t he o utc o mes liste d 
a b o ve  
7. 1. 3  Pre g n a nc y  
If a patie nt bec o mes pre g na nt d uri n g t he st u d y, st u d y dr u g a d mi nistrati o n m ust be disc o nti n ue d 
a n d t he p re g na n c y m ust  be re p orte d i m me diatel y ( wit hi n 2 4  h o urs  of b ec o mi n g a ware of t h e 
pre g na nc y) t o  Pfizer Safet y p ortal s yste m b y usi n g t h e F D A 3 5 0 0 A ( Me d Watc h F or m).  E ver y 
eff ort s h o ul d be ma de t o f oll o w t he patie nt t hr o u g h res ol uti o n of t he pre g na nc y (ter mi nati o n or 
deli ver y) a n d re p ort t he res ol uti o n of t he F D A 3 5 0 0 A ( Me d Watc h F or m) t o Pfizer Safet y p ortal 
s yste m ( ). 
7. 2   A d verse E ve nt a n d Pre g n a nc y Re p orti n g  
A d verse e v e nts will be gra de d acc or di n g t o C T C A E v 5 .  B ot h Seri o us a n d N o n -Seri o us A d verse 
E ve nts will be clearl y  n ote d i n s o urce d o c u me nt ati o n a n d liste d o n st u d y s pecific Case Re p ort 
F or ms ( C R Fs).  T he Pr ot oc ol Direct or ( P D) or d esi g nee will ass ess eac h A d verse E ve nt ( A E) t o 
deter mi ne w het her it is u ne x pecte d acc or di n g t o t he I nf or me d C o nse nt, Pr ot oc ol D oc u me nt, or  
I n v esti gat or’s Br oc h ure, a n d relate d t o t he i n vesti gati o n.  All Seri o us A d verse E ve nts ( S A Es) 
will be trac ke d u ntil res ol uti o n, or u ntil 3 0 da ys aft er t he last d ose of t h e st u d y treat me nt.  
S A Es C T C A E Gra de  3 a n d a b o ve, a n d all s u bse q ue nt f oll o w -u p re p ort s will be re p orte d t o t he 
Sta nf or d Ca ncer I nstit ute Data a n d Safet y M o nit ori n g C o m mittee ( D S M C) usi n g t he st u d y 
s pecific C R F wit hi n 2 4  h o urs of n otificati o n of e v e nt re gar dless of t he e v e nt’s relate d n ess t o t he 
i n vesti gati o n.  Please f oll o w ste ps i n A p pe n d i x B: Sta nf or d Ca n cer I nstit ute S A E re p orti n g 
g ui deli nes f or i n vesti gat or-i nitiate d trials.  
I n i n vesti gat or I N D st u dies, talaz o pari b seri o us, relate d, u nla bele d, ( u ne x pecte d) a d v erse e ve nts 
will be re p orte d t o t he F D A as re q uire d b y 2 1 C F R § 3 1 2. 3 2 b y t he I n v esti gat or  wit hi n 2 4  h o urs of 
n otificati o n of t he e v e nt.  T he  Me d Watc h  F or m ( F or m  3 5 0 0 A Ma n d at or y Re p orti n g) a n d 
F D A  F or m  1 5 7 1 m ust be c o m plete d a n d se nt t o t h e F D A.  
All S A Es (e x pecte d or u ne x pecte d, ca usall y rel ate d or n ot) a n d pre g n a nc y re p orts m ust al s o be 
re p orte d t o Pfizer Safet y p ortal s yste m, , a n d fa x e d t o Pfizer 
 wit hi n 2 4  h o urs  of t he I n vesti gat or’s a ware ness.   Pfizer will re vie w t h e A E d ata as 
d oc u me nte d i n t he site’s fi nal st u d y re p ort.  
F or C o m parat or Dr u gs/ Sec o n dar y S us pects ( C o nc o mita nt Me dicati o ns), all seri o us a d verse 
e x perie nces will be f or war de d t o t he pr o d u ct ma n ufact ur er.  
T he peri o d d uri n g w hic h all n o n -seri o us A Es a n d S A Es will be re p orte d be gins after i nf or me d 
c o nse nt is o btai ne d a n d will c o nti n ue t hr o u g h 3 0  da ys after t he last st u d y visit or 3 0 da ys aft er 
t he last d ose of st u d y m e dicati o n, w hic he ver c o m es first. 
I R B-3 1 9 1 3 versi o n 8  P a ge 3 6  of 4 6   2  Se pte m ber  2 0 2 0  7. 3   Pr o d uct C o m pl ai nts Re p orti n g  
A pr o d uct c o m plai nt (“ C o m plai nt”) is a n y direct, writte n, electr o ni c, or oral c o m m u nicati o n of 
dissatisfacti o n t hat alle ges deficie ncies rel ate d t o t he i de ntit y, q ualit y, d ura bilit y, la beli n g, p urit y, 
sta bilit y, a p p eara nce, effecti ve ness, s afet y, a n d/ or desi g n of a dr u g pr o d uct after it is release d f or 
d istri b uti o n.  
C o m plai nts t hat si m ulta ne o usl y fall u n der A d verse E ve nt defi niti o ns u n der t his Pr ot oc ol nee d 
o nl y be re p orte d vi a t he A d verse E v e nt re p orti n g pr oce d ure set f ort h i n t his Pr ot oc ol.   
I n v esti gat or or desi g nee ( Re p orter) s h all ca pt ure t he f oll o wi n g C o m plai nt i nf or mati o n as relates 
t o talaz o pari b ( B M R N 6 7 3 ) use d u n der t his Pr ot o c ol:  
• Date c o m plai nt recei ve d  
• Pr o d uct Na me a n d L ot N u m ber  
• I n dicate if t he pr o d uct is a vaila ble f or ret ur n t o Pfi zer f or i n vesti gati o n  
• Q ua ntit y Affecte d  
• Detaile d Des cri pti o n  of c o m plai nt  
• St u d y Pr ot o c ol N u m ber  
• I n v esti gat or Na me 
• Site C o ntact  
• Site N u m ber  
• S u bject N u m ber  
• Na me a n d c o ntact i nf or mati o n of t he pers o n w h o is re p orti n g t he c o m plai nt as well as 
na me a n d c o ntact i nf or mati o n of t he c o m plai n a nt.  T he re p orter will be c o nta cte d b y 
Pfizer Pr o d uct C o m plai nt Q ualit y Ass ura nce De p art me nt.  
I n v esti gat or or desi g nee ( Re p orter) will use his or her b est eff orts t o re p ort C o m plai nts t o Pfizer 
wit hi n fi ve da ys of l ear ni n g of t he C o m plai nt .  I n v esti gat or or desi g nee will s u b mit t he c o mplai nt 
i nf or mati o n b y e mail.  
8 .  C O R R E L A TI V E   S T U DI E S  
T his st u d y is d esi g n e d t o assess h ere ditar y a n d s o matic defects i n ge nes t hat s u p p ort  
h o m ol o g o us rec o m bi nati o n d o u ble -stra n d brea k re pair defects be y o n d B R C A a n d t heir 
i m plicati o n i n t u m ori ge n esis.  T he g oal is t o use s uc h i de n tifia ble defects as bi o mar kers t o tail or 
dr u g t hera p y  utilizi n g t he pri nci ple of s y nt hetic let halit y ; i n t his case wit h talaz o pari b, a p ote nt 
P A R P i n hi bit or .  C orrelati ve st u dies will be c o n d ucte d t o assess u n d erl yi n g ger mli ne  m u tati o ns, 
ge n o mic i nsta bilit y  as assesse d b y t h e t u m or  H R D  sc ore, a n d res p o nse t o dr u g .  All partici p a nts 
will be as ke d t o pr o vi de a bl o o d sa m ple t o r u n t he m y Ris k here ditar y 2 5 -ge ne pa n el  o n a 
researc h basis.  T he m y Ris k here ditar y 2 5 -ge n e pa nel  e val uat es a br oa d n u m ber of here ditar y 
ca ncer s y n dr o mes i ncl u di n g se v eral ge n es i m plicate d i n  H R d o u ble -stra n de d D N A re pair .  A 
se parat e res earc h ger mli ne  bl o o d sa m ple  a n d plas ma sa m ple  will als o be c ollecte d .  F urt her m ore , 
all partici pa nts will be as ke d t o pr o vi de an a de q u ate  metastatic t u m or  bi o ps y t o assess t he  H R D  
sc ore base d o n t he H R D  assa y a n d R A D 5 1 stat us .  O nl y i n cases w here a metastatic bi o ps y is n ot 
tec h nicall y feasi ble will t he H R D  sc ore or R A D 5 1 stat us  be assesse d o n t he pri mar y t u m or .  All 
s u bjects will be as ke d t o s u b mit a n arc hi val s a m ple of t heir pri mar y breast t u m or.  T he R A D 5 1 
I R B-3 1 9 1 3 versi o n 8  P a ge 3 7  of 4 6   2  Se pte m ber  2 0 2 0  stat us of t he t u m or will be assesse d usi n g i m m u n o hist oc he mistr y at baseli ne (a bse nt or prese nt) 
as a f u ncti o nal r ea d o ut of  H R ca pacit y a n d t his will be c orrelate d wit h  H R D  stat us.  
All c orrelati ve e n d p oi nts will be meas ure d usi n g u ni variate a n d m ulti variate l o gisti c re gressi o n 
m o dels , rec o g nizi n g t hat t hese are e x pl orat or y a n al yses a n d t h us ma y be i ns ufficie ntl y p o were d 
f or statistical p ur p oses.  F or s pecifi c c orrelati ve e n d p oi nts  a nd t he statistical met h o ds use d f or 
e val uati o n, please refer t o Secti o n  1 2 . 3. 
Tiss ue bi o psies, w h ole bl o o d a n d plas ma will be s a m ple d i n t his st u d y .  T h e y will be st ore d a n d 
ma y b e use d f or f ut ure researc h p ur p os es pr o vi de d t he patie nt has gi ve n his/ h er c o nse nt .  All 
s uc h sa m ples will be la bele d wit h a u ni q ue n u meric i de ntifier t hat will be c o de d f or patie nt 
pri vac y .  O nl y a ut h orize d st u d y pers o n nel will ha ve access t o t hese tiss ues.  If t he patie nt 
decli nes t his o pti o n, re mai ni n g tiss ue a n d bl o o d will  be discar de d after s pecifie d c orrelati ve 
st u d y pr oce d ures ha ve b ee n perf or me d. 
I R B-3 1 9 1 3 versi o n 8  P a ge 3 8  of 4 6   2  Se pte m ber  2 0 2 0  9.   S T U D Y C A L E N D A R  
 
Pre -St u d y 
Scree ni n g  C ycle 1  
( 1 c ycle = 2 8 d a ys) 
+/ - 3 d a ys  C ycle 2  
( 1 c ycle = 2 8 d a ys) 
+/ - 3 d a ys  C ycle 3  t o 3 6  
( 1 c ycle = 2 8 
d a ys)  
+/ - 3 d a ys  E n d of  
St u d y  b 
 D a ys -2 8 t o 0  D 1   D 8   D 1 5   D 2 2   D 1   D 1 5   D 1    
I nf or me d c o nse nt X               
De m o gra p hics  X               
Me dical hist or y  X              
Fa mil y hist or y  X               
C o nc urre nt me ds  X               
Tala z o pari b dis pe nsi n g a n d dail y d osi n g 
f or 2 8 da ys st arti n g c ycle Da y  1    X         X    X   
P h ysical e xa m  X   X     X     X    X   X  
Vital si g ns  X   X     X     X    X   X  
Hei g ht  X                
Wei g ht  X   X     X     X    X   X  
P erf or ma nce stat us  X   X     X     X    X   X  
C B C w/ diff  ( +/ - 3 da ys)  X   X   X   X   X   X   X   X   X  
Ser u m c he mistr y  a ( +/- 3 da ys)  X   X     X     X    X   X  
A d verse e ve nt e val u ati o n     X     X     X    X   X  
Uri ne pre g na nc y ( w o me n of 
c hil d beari n g p ote ntial)  X   X       X  X   X 
Assess me nt of  H R D  sc ore usi n g H R D  
assa y fr o m c ore bi o ps y of metastatic 
site.  If a n a de q uate metastatic bi o ps y 
is n ot a vaila ble, a fres h bi o ps y will be 
perf or me d.  Res ults ar e re q uire d pri or 
t o treat me nt i nitiati o n f or C o h ort A 
o nl y.  X               
S u b missi o n of arc hi val t u m or sa m ple of 
pri mar y t u m or  X               
M yria d M y Ris k bl o o d c ollecti o n  X               
W h ole bl o o d c ollecti o n  X               
Plas ma c ollecti o n  X              X  
T u m or meas ure me nts  X  T u m or meas ure me nts are re peate d e ver y 8 we e ks t hr o u g h 
c ycle 8 ( o pti o n t o re peat e ver y 1 2 we e ks after c ycle 8).  
D oc u me ntati o n m ust b e pr o vi d e d f or patie nts re m o ve d fr o m 
st u d y f or pr o gressi ve diseas e. X  
Ra di ol o gic e val u ati o n ( C T wit h I V 
c o ntrast a nd b o ne sca n or  P E T C T 
wit h I V c o ntrast, pl us M RI brai n or 
C T h ea d if hist or y of brai n 
metastas es).  X  Ra di ol o gic meas ure me nts s h o ul d be perf or me d e ver y 8  wee ks 
±  1  wee ks.  T here is t he o pti o n t o decrease ra di ol o gic e val u ati o n 
t o e ver y 1 2 wee ks after c ycle 8.  X  
a. Al b u mi n, al kali ne p h os p hatase, t otal bilir u bi n, bicar b o nate, B U N, calci u m, c hl ori d e, creati ni ne, gl u c ose, p otassi u m, t otal pr otei n, 
S G O T[ A S T], S G P T[ A L T], s o di u m.  
b .  T o be c ollecte d at first cli nic visit after e vi d e nce of disease pr o gressi o n ( ±  7  da ys).  
I R B-3 1 9 1 3 versi o n 8  P a ge 3 9  of 4 6   2  Se pte m ber  2 0 2 0  1 0 .  M E A S U R E M E N T S  
1 0 . 1 Pri m ar y E n d p oi nt  
T he o bjecti ve res p o nse r ate of t al az o p ari b defi ne d as c o m plete res p o nse or p arti al res p o nse 
per  R E CI S T v 1. 1  
O bjecti ve res p o nse rate is defi ne d as c o m plete res p o nse or partial res p o nse a n d deter mi ne d b y 
R E CI S T  v 1. 1 criteri a.  All st u d y p artici pa nts will ha ve meas ura ble disease at st u d y i nitiati o n.  
O bjecti ve res p o ns es are defi ne d usi n g R E CI S T v. 1. 1 criteria:  
  C o m plete Res p o nse ( C R): Disa p peara nce of all tar get lesi o ns .  A n y p at h ol o gical l y m p h 
n o des ( w het her tar get or n o n -tar get) m ust ha v e re d ucti o n i n s h ort a xis t o <  1 0 m m.  
  Partial Res p o nse ( P R):  At least a 3 0 % decrease i n t he s u m of dia meters of tar get lesi o ns, 
ta ki n g as refere n ce t he baseli ne s u m dia meters.  
  Pr o gressi ve Diseas e ( P D): At least a 2 0 % i ncrease i n t he s u m of dia meters of tar get lesi o ns, 
ta ki n g as refere n ce t he s mallest s u m o n st u d y (t his i ncl u des t he baseli ne s u m if t hat is t he 
s mallest o n st u d y).  I n a d diti o n t o t he relati ve i ncrease of 2 0 %, t he s u m m ust als o 
de m o nstrate a n a bs ol ute i ncreas e of a t least 5 m m.  ( N ote: t he a p peara nce of o ne or m ore n e w 
lesi o ns is als o c o nsi dere d pr o gressi o n)  
C o nfir mati o n of a res p o nse re q uires a re p eat o bser vati o n at least 4 wee ks a part.  
F or t he p ur p oses of t his st u d y, patie nts s h o ul d be e val uate d f or res p o nse at 8  wee ks  +/ - 1  wee k, 
t he n re-e val u ate d f or res p o nse e ver y 8  wee ks  +/ - 1  wee k, or s o o n er if t here is a cli nical or 
la b orat or y fi n di n g t hat is c o ncer ni n g f or dise ase pr o gressi o n.  T he t y pe of i ma gi n g m o dalit y is 
de pe n de nt o n sites of metastases b ut will mai nl y  c o nsist of C T c hest, a b d o me n a n d pel vis wit h 
c o ntrast a n d b o n e sca n or P E T C T wit h I V c o ntrast .  All baseli ne e val uati o ns s h o ul d be 
perf or me d as cl os el y as p ossi ble t o t he be gi n ni n g of treat me nt a n d ne v er m ore t h a n 4  wee ks 
bef ore i nitiati o n.  
Res p o nse a n d pr o gressi o n will be e val uat e d i n t his st u d y usi n g t he i nter nati o nal criteria pr o p ose d 
b y t h e re vise d Res p o nse E val uati o n Criteria i n S oli d T u m ors ( R E CI S T) g ui deli ne 
(v ersi o n 1. 1).  2 9  C ha n ges i n t he lar gest dia meter ( u ni -di me nsi o nal meas ure me nt) of t he t u m or 
lesi o ns a n d t he s h ortest dia meter i n t he cas e of mali g na nt l y m p h n o d es are us e d i n t he R E CI S T 
criteria.  T he Eise n ha uer 2 0 0 9 E ur o pea n J o ur nal of Ca ncer ma n uscri pt details t he c o m plete 
descri pti o n of R E CI S T  v 1. 1 criteria f or res p o ns e assess me nt a n d will be f oll o we d f or t his st u d y.  
1 0. 2  Sec o n d ar y E n d p oi nts  
1 0. 2. 1  Cli nic al be nefit r ate ≥  2 4  wee ks  
T his is defi ne d as c o m plete res p o nse, partial res p o nse or sta ble diseas e as assesse d after at least 
2 4  wee ks o n t he i n vesti gati o nal dr u g .  R es p o nse a n d pr o gressi o n will be e v al uate d usi n g 
R E CI S T  g ui deli ne v 1. 1 .  I ma gi n g will be perf or me d e ver y 8  wee ks .  
1 0 . 2.2  P r o g ressi o n -free s ur vi v al 
Pr o gressi o n -free s ur vi val is defi ne d as t he ti me fr o m ra n d o mizati o n t o d oc u me nte d diseas e 
pr o gressi o n or deat h.   Patie nts wit h o ut pr o gressi o n at t he e n d of t he st u d y will be ce ns ore d at t he 
date of t heir last ra di o gra p hic e val uati o n.  
I R B-3 1 9 1 3 versi o n 8  P a ge 4 0  of 4 6   2  Se pte m ber  2 0 2 0  1 0 . 2.3  S afet y of t al az o p ari b i n t his st u d y p o p ul ati o n 
All a d verse e ve nts will be gra de d acc or di n g t o C T C A E  v 5 . 
1 0. 3  C orrel ati v e E n d p oi nts  
1 0. 3. 1  O bjecti ve res p o nse r ate i n s u bjects wit h T N B C wit h or wit h o ut a n  u n derl yi n g 
ger mli ne  H R p at h w a y m ut ati o n i n C o h ort  A  
T he 2 5 -ge n e M y Ris k ger mli ne  m utati o n pa nel will be perf or m e d o n all s u bjects o n a res earc h 
basis i n C o h ort  A .  O bjecti ve res p o nse rates b y R E CI S T v 1. 1 will be c o m pare d i n s u bjects wit h 
a n d wit h o ut a n i de ntifie d  H R pat h wa y ge n e m ut ati o n of i nterest.  
1 0. 3. 2  C orrel ati o n of  H R D  sc o res wit h res p o nse i n s u bjects wit h u n derl yi n g deleteri o us  or 
s us pecte d deleteri o us  ger mli ne  or s o m atic  H R g e ne m ut ati o ns i n C o h ort  B  
T he  H R D  sc ore is a c o nti n u o us meas ure me nt ( 0 t o 1 0 0) t hat will be assesse d fr o m metastatic 
F F P E t u m or tiss ue usi n g t he M yri a d  H R D  assa y o n a researc h b asis i n s u bjects e nr olle d o n 
C o h ort  B .  Base d o n pri or st u dies, a n  H R D  c ut off sc ore of 4 2  or hi g h er will be use d t o defi ne  
H R -deficie nt breast c a ncer .  We will c orrel ate t he mea n  H R D  sc ores a n d di c h ot o m o us H R D  
sc ores (H R D  d eficie n t v ers us H R D  i ntact) wit h t hera p y res p o nse. 
1 0. 3. 3  C orrel ati o n of  H R D  sc o res i n t he pri m ar y t u m o r tiss ue a n d t he met ast atic t u m or 
tiss ue. 
All s u bjects will ha ve b ot h metastatic a n d arc hi val pri mar y breas t t u m or sa m ples assesse d 
f or H R D .  We will assess t he c orrelati o n of sc ores ( mea n a n d dic h ot o m o us sc ores) f or t hese t w o 
t u m or sa m ple t y pes wit hi n eac h p atie nt.  Patie nts i n w h o m a metastatic bi o ps y was dee me d n ot 
feasi ble will be e x cl u de d. 
1 0. 3. 4  C orrel ati o n of R A D 5 1 st at us i n t he met ast ati c t u m or wit h  H R D  a n d m ut ati o n al 
st at us. 
R A D 5 1 b y i m m u n o hist oc he mistr y as a f u ncti o nal rea d o ut of  H R ca pacit y will be assesse d i n 
baseli ne F F P E metastatic t u m or bi o ps y sa m ples .  R A D 5 1 stat us, a bse nt or prese nt, will be 
c orrel ate d wit h H R D  a n d m utati o nal stat us.  
1 1 .  R E G U L A T O R Y C O N SI D E R A TI O N S  
1 1 . 1 I nstit uti o n al Re vie w of Pr ot oc ol 
T he pr ot oc ol, t he pr o p os e d i nf or me d c o ns e nt a n d all f or ms of partici pa nt i nf or mati o n relate d t o 
t he st u d y (e g, a d vertise m e nts use d t o recr uit p arti ci pa nts) will be re vie we d a n d a p pr o ve d b y t h e 
Sta nf or d I R B a n d Sta nf or d Ca ncer I nstit ute Scie ntific Re vie w C o m mittee ( S R C).  A n y c ha n ges 
ma de t o t he pr ot oc ol will be s u b mitte d as a m o dificati o n a n d will be a p pr o ve d b y t he I R B pri or 
t o i m ple me ntati o n.  T he Pr ot oc ol Direct or will disse mi nate t he pr ot oc ol a me n d me nt i nf or mati o n 
t o all partici pati n g i n vesti gat ors. 
1 1 . 2 D at a a n d S afet y M o nit ori n g Pl a n  
T he Sta nf or d Ca n cer I nstit ute Data a n d Safet y M o nit ori n g C o m mittee ( D S M C) will be t he 
m o nit ori n g e ntit y f or t his st u d y.  T he D S M C will a u dit st u d y -relate d acti vities t o deter mi ne 
w het her t he st u d y has bee n c o n d ucte d i n acc or da nce wit h t he pr ot oc ol, l ocal sta n dar d o perati n g 
pr oce d ures, F D A re g ulati o ns, a n d  G o o d Cli nical Practice  ( G C P).  T his ma y i ncl u de re vie w of t he 
f oll o wi n g t y pes of d oc u me nts partici pati n g i n t he st u d y: re g ulat or y bi n d ers, case re p ort f or ms, 
I R B-3 1 9 1 3 versi o n 8  P a ge 4 1  of 4 6   2  Se pte m ber  2 0 2 0  eli gi bilit y c h ec klists, a n d s o urce d oc u me nts.  I n a d diti o n, t he D S M C will re g ularl y re vie w 
seri o us a d verse e ve nts a n d pr ot oc ol de vi ati o ns ass ociate d wit h t he re searc h t o e ns ure t he 
pr otecti o n of h u ma n s u bjects.  Res ults of t he D S M C a u dit will be c o m m u nicate d t o t he I R B a n d 
t he a p pr o pri ate re g ulat or y a ut h orities at t he ti me of c o nti n ui n g re vi e w, or i n a n e x pe dite d 
fas hi o n, as nee de d. 
1 1 . 3 D at a M a n a ge me nt Pl a n  
Elec tr o nic Cas e Re p ort F or ms ( C R Fs) will be us e d t o rec or d all pr ot o c ol -relate d i nf or mati o n o n 
eac h trial partici pa nt .  C R Fs will s u m marize t he cli nical fi n di n gs a n d o bser vati o ns necessar y t o 
e ns ure safet y of partici pa nts o n t he st u d y, a n d t o d oc u me nt t he st u d y o utc o mes.  
Re d Ca p Electr o nic Cas e Re p ort F or ms (e C R F) will be us e d t o rec or d all pr ot oc ol -relate d 
i nf or mati o n o n eac h tri al partici pa nt.  A C R F will be c o m plete d f or eac h e nr olle d st u d y 
partici pa nt .  It is t he i n vesti gat or's res p o nsi bilit y t o e ns ure t he acc urac y, c o m plete ness, clarit y, 
a n d ti meli ness of t h e dat a re p orte d i n t h e partici pa nt's C R F .  S o urce d o c u me ntati o n s u p p orti n g 
t he C R F dat a s h o ul d i n dicate t he patie nt's p arti ci pati o n i n t he st u d y a n d s h o ul d d oc u me nt t h e 
date a n d det ails of st u d y pr oce d ur es, A Es, ot her o bser vati o ns a n d patie nt st at us.  
T he i n vesti gat or is re q uire d t o pre pare a n d mai ntai n a de q uate a n d acc urate case hist ories 
desi g ne d t o rec or d all o bser vati o ns a n d ot h er data perti ne nt t o t he st u d y f or eac h st u d y 
partici pa nt .  T he st u d y data f or eac h e nr olle d partici pa nt will be e ntere d i nt o a C R F b y site 
pers o n nel usi n g a sec ure, vali date d, we b -bas e d electr o nic data ca pt ur e a p plicati o n .  A n y c ha n ges 
t o st u d y d ata will be ma de t o t he C R F a n d d oc u me nte d i n a n a u dit trail t hat will be mai ntai ne d 
wit hi n t he cli nical data base.  
1 2 .  S T A TI S TI C A L C O N SI D E R A TI O N S  
1 2 . 1 A n al ytic Pl a n f or St u d y O bjecti ves  
1 2. 1. 1  Pri m ar y O bjecti ve  
T o deter mi ne t he o bjecti ve res p o nse rate, defi ne d as c o m plete res p o nse or  partial  res p o nse per 
R E CI S T 1. 1 , t he o bjecti ve res p o ns e rate a n d 9 5 % c o nfi de nce i nter val will be calc ul ate d usi n g t he 
e x act bi n o mial m o del.   
1 2. 1. 2  Sec o n d ar y O bjecti ves  
T o deter mi ne t he cli nical be nefit rate, defi n e d as c o m plete res p o nse, partial res p o nse or sta ble 
disease ≥  2 4  wee ks per R E CI S T  v 1. 1 , t he clinical be nefit rate a n d 9 5 % c o nfi de nce i nter val will 
be calc ul ate d usi n g t h e e x act bi n o mial m o del.   
T o deter mi ne pr o gressi o n -free s ur vi val, Ka pla n -Meier  c ur ves will be calc ulate d , al o n g wit h a 
9 5 % c o nfi de n ce i nter val f or P F S at o ne year, calc ulate d usi n g G ree n w o o d’s f or m ula.   
T o assess safet y of t alaz o pari b i n t his st u d y p o p ulati o n, ad verse e v e nts will be gra d e d usi n g 
C T C A E v 5  a n d s u m marize d descri pti vel y as descri be d i n Secti o n  7. 1.  
1 2. 1. 3  C orrel ati v e O bjecti v es  
I n c orrelati n g H R D  sc ore (ra n gi n g o ver 0 t o 1 0 0) wit h a bi nar y vari a ble s u c h o bjecti ve res p o nse 
stat us, R A D 5 1 stat us a n d s o o n, we will calc ulate t he mea n a n d sta n d ar d de viati o n of  H R D  sc ore 
i n t he t w o s u bsets a n d e v al uate t he stre n gt h of t h e ass ociati o n usi n g t he Wilc o x o n ra n k s u m 
statistic.  
I R B-3 1 9 1 3 versi o n 8  P a ge 4 2  of 4 6   2  Se pte m ber  2 0 2 0  I n eval uati n g t he c o n c or da nce of  H R D  sc ore i n t he pri mar y t u m or a n d H R D  i n t he metastatic 
t u m or, t he Wilc o x o n si g ne d ra n k test will be use d. 
All re mai ni n g c o m paris o n i n v ol ve c orrel ati n g t w o bi nar y v aria bl es, w hic h will be d o n e b y 
prese nti n g pr o p orti o ns wit h 9 5 % e x act c o nfi de nce i nter vals .  T he si g nifica n ce of t he c orrelati o n 
will be assesse d usi n g Fis her’s e x act test.   A t w o -si de d P val ue of 5 % or less will be c o nsi dere d 
statisticall y si g nifica nce. 
T he p r o p orti o n of s pecific mutati o ns wit h its 9 5 % c o nfi de nce i nter val will be calc ulate d usi n g 
t he e x act bi n o mial m o del. 
1 2 . 2 A n al ysis p o p ul ati o n   
Safet y a n al ysis will be c o n d ucte d o n all patie nts w h o recei ve d at l east o n e d ose of tri al t hera p y .  
Efficac y a n al ysis will be perf or me d o n all patie nts w h o recei ve at least 1 c ycl e of t hera p y u nl ess 
t he reas o n f or c o m pleti n g less t ha n 1 c ycle of t h era p y was attri b uta ble t o disease pr o gressi o n.  
Patie nts w h o c o me off trial bef ore c o m pleti n g 1 c ycle of t hera p y f or reas o ns ot her t ha n disease 
p r o gressi o n will be c o nsi dere d n o n-e val ua bl e f or res p o nse a n d will be re place d.  
1 2 . 3 S a m ple Size C alc ul ati o ns  
T his p hase  2  pr o of -of -c o nce pt trial is a n o pe n -la bel st u d y i n patie nts wit h a d va nce d, 
H E R 2 -ne gati ve breast ca ncer or n o n -breast metastatic ca ncer .  A t w o -sta ge desi g n will be use d 
f or e nr oll me nt of st u d y partici pa nts se paratel y i n C o h ort  A a n d  i n C o h ort  B wit h a set 
n ull  h y p ot hesis of   5 % o bjecti ve res p o nse rate a n d alter nati ve res p o ns e rate of   3 0 % base d o n 
sta n dar d R E CI S T v 1. 1 criteria.  
I nteri m anal ysis will be perf or me d, se paratel y i n eac h c o h ort, after accr ual of 1 0  patie nts a n d 
ha ve ha d at least o ne res p o nse assess me nt i n t hat c o h ort.  P atie nts will be o bser ve d f or res p o ns es 
e ver y 8  wee ks +/ - 1  wee k .  If at least t w o o ut of t he 1 0  patie nts r es po n ds, t he n we will accr ue 
1 0  a d ditio nal patie nts f or a t otal of 2 0  patie nts i n eac h c o h ort (t otal n u m ber of patie nts f or t he 
trial =  4 0) .  Bas e d o n o ur statistical c o nstrai nts, at least 3  patie nts o ut of t he 2 0 res p o n d i n eac h 
c o h ort t o declare statistical  si g nifica nce at a o ne-si de d 5 % le vel wit h 8 0 % p o wer or b etter 
1 2 . 4  Accr u al Esti m ates a n d Fe asi bilit y     
We see >  7 5 ne w patie nts wit h a d va nce d, tri ple -ne gati ve breast ca n cer at t he Sta nf or d W o me n’s 
Ca ncer Ce nter eac h year a n d fr o m 2 0 0 9  t o 2 0 1 3 h a ve c o nsis te ntl y e nr olle d >  2 5 patie nts p er year 
t o tri ple-ne gati ve s pecifi c cli nical trials.  Base d o n o ur pre vi o us ne oa dj u va nt st u d y utilizi n g 
t he H R D  assa y, a p pr o xi matel y half of s p ora dic, tri ple -ne gati ve breast ca ncer patie nts ha ve 
a n H R D  sc ore t hat is greater tha n or e q u al t o 4 2 .  As s uc h we are c o nfi de nt t hat we ca n accr ue 
o ur  patie nts i n t he pr oject e d ti meli ne pr o vi de d.  
Gi ve n t h at t he  utilizati o n of m ulti ple x  ge n e p a nels t o assess ger mli ne  m ut ati o ns i n t he H R re pair 
pat h wa y h as rece ntl y e mer ge d  a n d b eca us e t he  use of t u m or N G S is j ust rece ntl y o n t h e rise , we 
ha ve n o hist orical meas ures t o h el p esti mate t he n u m ber of patie nts we will be accr ue i n 
C o h ort  B wit hi n  o ur  si n gle i nstit uti o n.  T hat b ei n g sai d, we are e nc o u nteri n g a n i ncreasi n g 
n u m ber of t h ese p atie nts  t hr o u g h o ur Ca ncer Ge n o mics Pr o gra m.  We will w or k cl os el y wit h t he 
here ditar y ca n cer n o n -pr ofit or ga nizati o n F O R C E t o p u blicize t his trial .  S h o ul d accr ual be 
li mite d, we will c o nsi der a d di n g a d diti o nal st u d y sites t o c o m plete t his c o h ort accr ual. 
I R B-3 1 9 1 3 versi o n 8  P a ge 4 3  of 4 6   2  Se pte m ber  2 0 2 0  R E F E R E N C E S  
1.  F or d J M, Kasta n M B. D N A da ma ge res p o nse pat h wa ys a n d ca ncer. 4t h e d: C h urc hill 
Li vi n gst o n; 2 0 0 8.  
2.  As h w ort h A. A s y nt hetic let hal t hera pe utic a p pr oac h: p ol y( A D P) ri b ose p ol y m erase 
i n hi bit ors f or t he treat me nt of ca ncers deficient i n D N A d o u ble -str a n d brea k re pair. J o ur nal 
of cli nical o nc ol o g y : offi cial j o ur nal of t he A m eri ca n S ociet y of Cli nical O nc ol o g y 
2 0 0 8; 2 6: 3 7 8 5 -9 0.  
3.  Br ya nt H E, Sc h ultz N, T h o mas H D, et al . S pecifi c killi n g of B R C A 2-deficie nt t u m o urs wit h 
i n hi bit ors of p ol y( A D P-ri b ose) p ol y m eras e. Nat ur e 2 0 0 5; 4 3 4: 9 1 3-7.  
4.  Cleat or S, Heller W, C o o m bes R C. Tri ple -ne gati v e breast ca ncer: t hera pe utic o pti o ns. T he 
la ncet o nc ol o g y 2 0 0 7; 8: 2 3 5-4 4.  
5.  Far mer H, Mc Ca b e N, L or d CJ, et al . Tar geti n g t he D N A re pair d efect i n B R C A m utant cells 
as a t hera pe utic strate g y. Nat ure 2 0 0 5; 4 3 4: 9 1 7 -2 1.  
6.  L or d CJ, As h w ort h A. T he D N A da m a ge res p o ns e a n d ca ncer t hera p y. Nat ure 
2 0 1 2; 4 8 1: 2 8 7 -9 4.  
7.  R o ulea u M, Patel A, He n dzel MJ, Ka uf ma n n S H, P oirier G G. P A R P i n hi biti o n: P A R P 1 a n d 
be y o n d. Nat ur e re vie ws Ca ncer 2 0 1 0; 1 0: 2 9 3 -3 0 1.  
8.  F o ul kes W D, Stefa nss o n I M, C ha p p uis P O, et al . Ger mli ne  B R C A 1 m utati o ns a n d a basal 
e pit helial p he n ot y p e i n breast c a ncer. J o ur nal of t he Nati o nal Ca ncer I nstit ute 
2 0 0 3; 9 5: 1 4 8 2 -5.  
9.  S orlie T, Ti bs hira ni R, Par ker J, et al . Re peate d o bser vati o n of breast t u m or s u bt y pes i n 
i n de pe n de nt ge n e e x pressi o n data sets. Pr ocee di n gs of t he Nati o nal Aca de m y of Scie n ces of 
t he U nite d States of A merica 2 0 0 3; 1 0 0: 8 4 1 8-2 3.  
1 0.  Nielse n T O, Hs u F D, J e nse n K, et al . I m m u n o hist oc he mical a n d cli nical c haract erizati o n of 
t he basal-li ke s u bt y pe of i n vasi ve breast c arci n o ma. Cli nical Ca ncer Res earc h 
2 0 0 4; 1 0: 5 3 6 7 -7 4.  
1 1.  Hasta k K, Alli E, F or d J M. S y ner gistic c h e m ose nsiti vit y of tri ple -ne gati ve breast c a ncer cell 
li nes t o p ol y( A D P-Ri b os e) p ol y m eras e i n hi biti o n, ge m cita bi ne, a n d cis plati n. Ca ncer 
researc h 2 0 1 0; 7 0: 7 9 7 0-8 0.  
1 2.  Alli E, S har ma V B, S u n d eresa k u m ar P, F or d J M. Defecti ve re p air of o xi dati ve d na da ma ge 
i n tri ple-ne gati ve breast c a ncer c o nfers se nsiti vit y t o i n hi biti o n of p ol y( A D P -ri b ose) 
p ol y me rase. Ca ncer researc h 2 0 0 9; 6 9: 3 5 8 9-9 6.  
1 3.  Gel m o n K A, Tisc h k o wit z M, Mac ka y H, et al . Ol a pari b i n patie nts wit h rec urre nt hi g h-gra de 
ser o us or p o orl y differe ntiate d o varia n carci n o ma or tri ple-ne gati ve breast ca ncer: a p has e 2, 
m ultice ntre, o pe n -la bel, n o n-ra n d o mise d st u d y. T he la ncet o n c ol o g y 2 0 1 1; 1 2: 8 5 2-6 1.  
1 4.  Castera L, Kri e ger S, R o usseli n A, et al . Ne xt-ge n erati o n se q ue n ci n g f or t h e dia g n osis of 
here ditar y breast a n d o varia n ca n cer usi n g ge n o mi c ca pt ur e tar geti n g m ulti ple ca n di date 
ge n es. E ur o pea n j o u r nal of h u ma n ge netics : EJ H G 2 0 1 4. 
1 5.  T u n g N, Bat elli C, Alle n B, et al . Pre val e nce of ge ne m utati o ns a m o n g here ditar y breast a n d 
o varia n ca ncer patie nts usi n g a 2 5 ge ne pa n el ( A bstract P D 4 -8).  Sa n A nt o ni o Breast Ca ncer 
S y m p osi u m; 2 0 1 3; Sa n A nt o ni o, T X.  
1 6.  A b ke vic h V, Ti m ms K M, He n ness y B T, et al . Patter ns of ge n o mic l oss of heter oz y g osit y 
pre dict h o m ol o g o us rec o m bi nati o n re pair defects i n e pit helial o varia n ca ncer. Britis h j o ur nal 
of ca ncer 2 0 1 2; 1 0 7: 1 7 7 6 -8 2.  
1 7.  Telli M, J e nse n K, A b ke vic h V, et al . H om ol o g o us Rec o m bi nati o n Deficie nc y ( H R D ) sc ore 
pre dicts pat h ol o gic res p o nse f oll o wi n g n e oa dj u va nt plati n u m -base d t hera p y i n tri ple -n e gati ve 
I R B-3 1 9 1 3 versi o n 8  P a ge 4 4  of 4 6   2  Se pte m ber  2 0 2 0  a n d B R C A 1/ 2 m utati o n -ass ociate d breast c a ncer ( B C).  Sa n A nt o ni o Breast Ca ncer 
S y m p osi u m; 2 0 1 2; Sa n A nt o ni o, T X.  
1 8.  Telli M L , J e nse n K C, K uria n A W. Pr E C O G 0 1 0 5: Fi nal efficac y res ults fr o m a p hase II 
st u d y of ge m cita bi ne ( G) a n d car b o pl ati n ( C) pl us i ni pari b ( B SI-2 0 1) as ne o a dj u va nt t hera p y 
f or tri ple-ne gati ve ( T N) a n d B R C A 1/ 2 m utati o n -ass ociate d breast ca n cer.  3 1. J o u r nal of 
cli nical o nc ol o g y : offici al j o ur nal of t he A merica n S ociet y of Cli nical O n c ol o g y 
2 0 1 3; 3 1: A bstract 1 0 0 3.  
1 9.  Telli M L , J e nse n K C, K uria n A W, et al . Pr E C O G 0 1 0 5: Fi nal effi cac y res ults fr o m a p hase II 
st u d y of ge m cita bi ne ( G) a n d car b o pl ati n ( C) pl us i ni pari b ( B SI-2 0 1) as ne o a dj u va nt t hera p y 
f or tri ple-ne gati ve ( T N) a n d B R C A 1/ 2 m utati o n -ass ociate d breast ca n cer.  A S C O A n n ual 
Meeti n g; 2 0 1 3; C hica g o, U S A: J Cli n O nc ol 3 1, 2 0 1 3 (s u p pl; a bstr 1 0 0 3).  
2 0.  S y m m a ns W F, Pei nti n ger F, Hatzis C, et al . Meas ure me nt of resi d ual breast ca ncer b ur de n t o 
pre dict s ur vi val after ne o a dj u va nt c he m ot hera p y. J o ur nal of cli nical o nc ol o g y : offi cial 
j o ur nal of t he A meri ca n S ociet y of Cli nical O n c ol o g y 2 0 0 7; 2 5: 4 4 1 4-2 2.  
2 1.  P o p o va T, Ma nie E, Rie u nier G, et al . Pl oi d y a n d l ar ge-s cale ge n o mic i nsta bilit y c o nsiste ntl y 
i de ntif y bas al-li ke breast carci n o mas wit h B R C A 1/ 2 i nacti vati o n. Ca ncer researc h 
2 0 1 2; 7 2: 5 4 5 4 -6 2.  
2 2.  Bir k ba k NJ, Wa n g Z C, Ki m J Y, et al . Tel o meric allelic i m bala nce i n dicates defecti ve D N A 
re pair a n d se nsiti vit y t o D N A -da m a gi n g a ge nts. Ca ncer disc o v er y 2 0 1 2; 2: 3 6 6 -7 5.  
2 3.  S he n Y, Re h ma n F L, Fe n g Y, et al . B M N 6 7 3, a n o vel a n d hi g hl y p ote nt P A R P 1/ 2 i n hi bit or 
f or t he treat me nt of h u ma n ca ncers wit h D N A re pair deficie nc y. Cli nical ca ncer researc h : a n 
official j o ur nal o f t h e A merica n Ass o ciati o n f or Ca ncer Res earc h 2 0 1 3; 1 9: 5 0 0 3-1 5.  
2 4.  S he n YJ, Fe n g Y, Wa n g B, C h u D, M yers P, P ost L. A bstract 3 5 1 4: L T -0 0 6 7 3, a hi g hl y 
p ote nt P A R P i n hi bit or, s h o ws a ntit u m or acti vit y a gai nst cells wit h D N A re pair defici e ncies.  
A A C R 1 0 1st  A n n ual Meeti n g: Ca ncer Researc h; 2 0 1 0; Was hi n gt o n D C.  
2 5.  Wai n ber g Z A, Rafi S, Ra ma nat ha n R K, et al . Safet y a n d a ntit u m or acti vit y of t he P A R P 
i n hi bit or B M N 6 7 3 i n a P hase I trial recr uiti n g m etastatic s mall-cell l u n g ca ncer ( S C L C) a n d 
B R C A m utati o n carrie r ca ncer patie nts.  A S C O A n n ual Meeti n g; 2 0 1 4; C hica g o. 
2 6.  T utt A, R o bs o n M, Gar ber J E, et al . Oral p ol y( A D P-ri b ose) p ol y m erase i n hi bit or ola pari b i n 
patie nts wit h B R C A 1 or B R C A 2 m utati o ns a n d a d va nce d breast c a ncer: a pr o of -of -c o nce pt 
trial. La ncet 2 0 1 0;3 7 6: 2 3 5 -4 4.  
2 7.  de B o n o J S, Mi na L A, G o nzalez M, et al . A bstract 2 5 8 0: First-i n-h u ma n trial of n o vel oral 
P A R P i n hi bit or B M N 6 7 3 i n patie nts wit h s oli d t u m ors. A S C O A n n ual Me eti n g; 2 0 1 3; 
C hica g o, I L.  
2 8. Pritc har d C C, Mate o J,  Wals h M F et al . I n h erite d D N A-Re p air Ge n e M utati o ns i n Me n wit h 
Metastatic Pr ostate Ca ncer. N EJ M 2 0 1 6; 3 7 5: 4 4 3 -4 5 3.  
2 9. Eise n ha uer E A, T herasse P, B o gaerts J, et al. Ne w res p o nse e v al uati o n criteria i n s oli d 
t u m o urs: re vise d R E CI S T g ui deli ne ( versi o n 1. 1). E ur J Ca ncer 2 0 0 9; 4 5( 2): 2 2 8-4 7  
 
I R B-3 1 9 1 3 versi o n 8  P a ge 4 5  of 4 6   2  Se pte m ber  2 0 2 0  A P P E N DI C E S  
I R B-3 1 9 1 3 versi o n 8  P a ge 4 6  of 4 6   2  Se pte m ber  2 0 2 0  A P P E N DI X A :   S A E Re p orti n g G ui deli nes; S CI S O P 1 0 -1 6 -2 0 1 4  
H O W T O R E P O R T S E RI O U S A D V E R S E E V E N T S ( S A E s)  
I N I N V E S TI G A T O R-I NI TI A T E D T RI A L S 
 1. D et er mi n e if t h e e v e nt m e et s crit eri a f or S A E i n St u d y pr ot o c ol a n d St a nf or d S O P  
( all S A E s Gr a d e  3 a n d a b o v e, m u st b e s u b mitt e d t o C C T O/ St a nf or d).  
 2. C o m pl et e A L L fi el d s of C C T O S A E C a s e R e p ort F or m  ( C R F) a n d v erif y wit h 
i n v e sti g at or.  
 3. C o nfir m wit h i n v e sti g at or S A E gr a d e, E x p e ct e d or U n e x p e ct e d a n d Attri b uti o n.  
 4.  O bt ai n i n v e sti g at or si g n at ur e o n t h e f or m aft er  filli n g o ut all t h e i nf or m ati o n. 
 5. S e n d si g n e d C C T O S A E f or m t o  vi a S E C U R E e m ail 
wit hi n 2 4  h o ur s of n otifi c ati o n o f t h e e v e nt. C C T O S af et y will e nt er it i nt o O n C or e. 
 6. V erif y wit h i n v e sti g at or if t h e S A E i s U n a nti ci p at e d Pr o bl e m  ( U P: u n e x p e cte d, 
r el at e d t o r e s e ar c h a n d h ar mf ul) a n d r e p ort it t o I R B, wit hi n 2 4  h o ur s of n otifi c ati o n 
of t h e e v e nt . 
  Cli c k o n r e p ort i n e Pr ot o c ol.  
  U pl o a d t h e c o m pl et e S A E r e p ort.  
  Fill o ut e Pr ot o c ol r e p ort f or m.  
  Cli c k o n “ S u b mit pr ot o c ol” b utt o n o n t h e l eft.  
 7. If S A E i s n ot U P, t h e n r e p ort d uri n g n e xt I R B r e n e w al.  
F or I n v e sti g at or -i niti at e d st u d y wit h a n I N D a n d If S A E i s U n a nti ci p at e d Pr o bl e m  
( U P) t h e n r e p ort t o F D A wit hi n 2 4 h o ur s of n otifi c ati o n of t h e e v e nt  
 8. C o m pl et e M e d W at c h F or m ( F or m 3 5 0 0 A) .  T h e f or m M U S T b e t y p e d!  F or 
a s si st a n c e c o nt a ct . A ct u al li n k f or t h e f or m:  
htt p s:// w w w. p dffill er. c o m/ e n/ pr oj e ct/ 1 5 0 7 0 0 5 2 0. ht m ?f h a s h = 7 a 4 e 5 d &r el o a d =tr u e   
 9. Wit h a s si st a n c e fr o m t h e r e g ul at or y f a cilit at or, s e n d t h e c o m pl et e d M e d W at c h 
f or m a n d F D A F or m  1 5 7 1 t o t h e F D A f oll o wi n g t h e w e b sit e i n str u cti o n s.  
 1 0. If r e q uir e d, n otif y m a n uf a ct ur er.  D e -i d e ntif y a p pli c a bl e s o ur c e d o c u m e nt s:  
M D  n ot e s ( a d mi s si o n, pr o gr e s s n ot e, di s c h ar g e n ot e, a n d d at e of d e at h 
if a v ail a bl e), l a b or at or y r e p ort s, r a di ol o g y r e p ort s, m e di c al a d mi ni str ati o n r e c or d s.  
 1 1. S e n d si g n e d C C T O S A E f or m  a n d d e -i d e ntifi e d s o ur c e d o c u m e nt s. 
 1 2. Fil e S A E r e p ort  i n p ati e nt r e s e ar c h c h art. 
 1 3. F oll o w S A E a n d s u b mit u p d at e d r e p ort s t o St a nf or d a n d/ or S p o n s or u ntil:  
  R e s ol uti o n of e v e nt.  
  R e s ol uti o n of e v e nt wit h s e q u el a e.  
  D e at h of p ati e nt.  
U nl e s s ot h er wi s e s p e cifi e d b y s p o n s or  